Andreas Schneeweiss

Q: What Schools Are Affiliated With Andreas Schneeweiss

Andreas Schneeweiss is affiliated with the following schools: Paracelsus Medical University, Queen Mary University of London, Karolinska Institute, University of Zurich, University of Cambridge, Heidelberg University, TU Dresden, Harvard University, Medical University of Vienna, Humboldt University of Berlin, University of Sheffield, Uppsala University, Heinrich Heine University Düsseldorf, Technical University of Munich, University of Erlangen–Nuremberg

Andreas Schneeweiss's AcademicInfluence.com Rankings

Andreas Schneeweiss

Philosophy

#6373

World Rank

#9402

Historical Rank

Logic

#3550

World Rank

#4731

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Andreas Schneeweiss's Degrees

Doctorate Medicine Harvard University
PhD Biomedical Sciences Harvard University

Why Is Andreas Schneeweiss Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Andreas Schneeweiss's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer (2018) (1567)
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. (2015) (1516)
Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer (2019) (1209)
Large-scale genotyping identifies 41 new loci associated with breast cancer risk (2013) (1063)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. (2018) (1030)
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay (2013) (926)
Association analysis identifies 65 new breast cancer risk loci (2017) (922)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). (2013) (882)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. (2013) (857)
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. (2010) (855)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. (2014) (751)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (616)
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes (2018) (559)
MicroRNA Related Polymorphisms and Breast Cancer Risk (2014) (557)
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer (2013) (534)
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients (2014) (517)
Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants (2015) (471)
Genome-wide association studies identify four ER negative–specific breast cancer risk loci (2013) (411)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. (2007) (380)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study. (2019) (360)
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial (2010) (344)
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. (2020) (322)
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. (2013) (305)
Genome-wide association analysis identifies three new breast cancer susceptibility loci (2012) (291)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. (2020) (287)
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. (2016) (284)
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial (2017) (281)
MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways (2012) (261)
Circulating microRNAs in plasma as early detection markers for breast cancer (2013) (253)
Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer (2012) (250)
Response-guided neoadjuvant chemotherapy for breast cancer. (2013) (232)
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. (2013) (225)
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. (2021) (224)
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. (2014) (222)
Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome (2012) (204)
Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: A randomized controlled trial (2015) (198)
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. (2011) (192)
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. (2010) (186)
Identification of Novel Genetic Markers of Breast Cancer Survival (2015) (185)
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto (2018) (182)
Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. (2006) (166)
A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer (2004) (159)
A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer (2018) (149)
Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis (2014) (141)
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use (2012) (138)
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. (2009) (136)
Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. (2004) (136)
Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study (2016) (134)
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. (2018) (132)
Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. (2011) (130)
Plasma MicroRNA Panel for Minimally Invasive Detection of Breast Cancer (2013) (128)
Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. (2016) (127)
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. (2021) (122)
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study (2021) (117)
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. (2012) (115)
The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer (2012) (114)
Muscle strength in breast cancer patients receiving different treatment regimes (2016) (114)
Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study (2011) (113)
Metabolic shifts in residual breast cancer drive tumor recurrence (2017) (113)
Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (2014) (112)
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses (2019) (110)
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. (2013) (109)
Targeted Therapies in Triple-Negative Breast Cancer (2015) (107)
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. (2020) (106)
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. (2009) (105)
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. (2021) (104)
Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial (2018) (104)
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. (2015) (103)
Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. (2011) (98)
13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus - Opinion of a German Team of Experts (Zurich 2013) (2013) (97)
The role of genetic breast cancer susceptibility variants as prognostic factors. (2012) (95)
Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130 (2019) (95)
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer (2013) (95)
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial (2015) (93)
LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC) (2020) (90)
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. (2011) (90)
Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial. (2010) (89)
Targeted Therapy in Breast Cancer (2010) (89)
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials (2015) (85)
Metastasis-initiating cells induce and exploit a fibroblast niche to fuel malignant colonization of the lungs (2020) (85)
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. (2018) (84)
Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. (2015) (84)
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. (2013) (83)
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial (2018) (83)
Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. (2002) (81)
Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. (2018) (80)
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer (2018) (80)
Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? (2016) (80)
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer (2016) (79)
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. (2019) (79)
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study (2014) (78)
Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2) (2017) (78)
Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study (2007) (77)
Abstract S2-04: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto) (2016) (76)
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2019) (74)
S5-6: Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA). (2011) (73)
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients (2015) (73)
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. (2019) (71)
Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients (2014) (71)
Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials (2015) (70)
Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. (2014) (70)
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). (2020) (68)
Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients (2014) (68)
Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility (2013) (68)
Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression (2003) (67)
IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). (2019) (67)
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019 (2019) (67)
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). (2021) (67)
Stress signaling in breast cancer cells induces matrix components that promote chemoresistant metastasis (2018) (66)
Prognostic factors for patients with liver metastases from breast cancer (2006) (65)
Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer (2017) (64)
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial (2016) (64)
Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. (2009) (64)
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer (2021) (62)
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer (2018) (61)
Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) (2012) (60)
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). (2014) (59)
Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences (2014) (58)
Self-reported physical activity behavior of breast cancer survivors during and after adjuvant therapy: 12 months follow-up of two randomized exercise intervention trials (2017) (58)
Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study (2005) (57)
Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab +nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer (2019) (57)
Helical Tomotherapy as a New Treatment Technique for Whole Abdominal Irradiation (2008) (56)
Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). (2017) (56)
DNA methylation array analyses identified breast cancer‐associated HYAL2 methylation in peripheral blood (2015) (55)
Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial (2010) (53)
Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program (2015) (53)
Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. (2018) (52)
Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial (2013) (52)
Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy? (2016) (51)
Abstract S6-5: Prognostic Relevance of Circulating Tumor Cells in the Peripheral Blood of Primary Breast Cancer Patients (2010) (51)
A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). (2013) (51)
Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: The German SUCCESS-Trial (2008) (51)
The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer (2017) (50)
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy (2019) (50)
Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2 (2015) (50)
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. (2018) (50)
Cardiorespiratory fitness in breast cancer patients undergoing adjuvant therapy (2014) (50)
S3-2: Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients - Results of the GeparTrio Trial. (2011) (49)
Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast (2014) (49)
Determinants of physical, affective, and cognitive fatigue during breast cancer therapy and 12 months follow‐up (2018) (48)
Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto. (2015) (47)
Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade (2016) (47)
The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features (2015) (47)
Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study (2009) (46)
Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. (2016) (45)
Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer (2018) (45)
Intrinsic breast cancer subtypes defined by estrogen receptor signalling—prognostic relevance of progesterone receptor loss (2013) (45)
Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial (2017) (45)
Genome-wide association study of germline variants and breast cancer-specific mortality (2019) (44)
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts (2015) (44)
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022 (2020) (44)
Personalized Therapy in Breast Cancer (2012) (44)
Outcome analysis of patients with primary breast cancer initially treated at a certified academic breast unit. (2012) (43)
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. (2015) (41)
Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour. (2013) (41)
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). (2019) (41)
Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network (2017) (41)
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021 (2021) (41)
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021 (2021) (41)
Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse (2008) (41)
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer (2018) (40)
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70) (2015) (39)
Acceptance of oral chemotherapy in breast cancer patients - a survey study (2011) (39)
The PACOVAR-trial: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer (2011) (38)
COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer (2018) (38)
Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus (2019) (38)
11q13 is a susceptibility locus for hormone receptor positive breast cancer (2012) (38)
The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial) (2007) (36)
PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer. (2020) (36)
Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2). (2019) (36)
A plasma metabolite panel as biomarkers for early primary breast cancer detection (2019) (36)
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial (2017) (36)
Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients (2016) (36)
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. (2010) (35)
350O_PRFINAL OVERALL SURVIVAL (OS) ANALYSIS FROM THE CLEOPATRA STUDY OF FIRST-LINE (1L) PERTUZUMAB (PTZ), TRASTUZUMAB (T), AND DOCETAXEL (D) IN PATIENTS (PTS) WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC) (2014) (35)
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis (2018) (35)
Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer. (2015) (35)
Progressive resistance versus relaxation training for breast cancer patients during adjuvant chemotherapy: design and rationale of a randomized controlled trial (BEATE study). (2013) (35)
Breast Cancers with a BRCA1-like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy (2014) (35)
Estrogen-related receptor alpha expression and function is associated with the transcriptional coregulator AIB1 in breast carcinoma. (2009) (35)
GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (H (2019) (34)
P53 is the strongest predictor of survival in high‐risk primary breast cancer patients undergoing high‐dose chemotherapy with autologous blood stem cell support (2002) (34)
Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients (2017) (34)
Heterogeneity of miR-10b expression in circulating tumor cells (2015) (34)
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry (2018) (34)
Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer. (2014) (34)
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial (2018) (34)
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). (2019) (33)
Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial (2013) (33)
Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer (2011) (33)
Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials (2017) (32)
FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer. (2010) (32)
Breast cancer and diabetes mellitus. (2010) (32)
Common germline polymorphisms associated with breast cancer-specific survival (2015) (31)
Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer (2012) (31)
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019 (2019) (31)
Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study (2014) (31)
LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer (2020) (30)
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. (2020) (30)
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER trial (2018) (30)
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). (2017) (30)
Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial. (2020) (30)
DNA methylation array analysis identifies breast cancer associated RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA (2016) (29)
Update Breast Cancer 2019 Part 3 – Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel (2019) (29)
Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer (2016) (28)
Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients (2016) (28)
Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study. (2010) (28)
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial (2018) (28)
The association between breast cancer and S100P methylation in peripheral blood by multicenter case–control studies (2017) (27)
Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model (2009) (27)
Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials (2018) (27)
Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy (2016) (27)
Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer (2014) (27)
Do patients with invasive lobular breast cancer benefit in terms of adequate change in surgical therapy from a supplementary preoperative breast MRI? (2012) (27)
Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. (2019) (26)
The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130. (2021) (26)
Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study. (2010) (26)
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. (2021) (26)
Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice (2019) (26)
Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study (2007) (26)
Abstract S3-1: Neoadjuvant Chemotherapy in the very young 35 years of age or younger (2012) (26)
Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III - The OVAR-IMRT-02 Study (2011) (26)
Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment. (2010) (25)
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. (2004) (25)
Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial. (2017) (25)
Omission of Axillary Dissection According to ACOSOG Z0011: Impact on Adjuvant Treatment Recommendations (2013) (25)
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. (2021) (25)
Abstract S1-09: Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A metaanalysis of 3771 patients (2017) (25)
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). (2016) (25)
9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium (2012) (24)
Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial. (2018) (24)
Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials (2019) (24)
Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications (2016) (24)
Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy (2004) (24)
Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention (2018) (24)
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab (2017) (23)
Abstract S2-07: A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69 (2015) (23)
Primary metastatic breast cancer in the era of targeted therapy - Prognostic impact and the role of breast tumour surgery. (2017) (23)
Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) – Pilot trial of a phase I/II study: study protocol (2007) (23)
Serum Levels of Hepatocyte Growth Factor/Scatter Factor in Patients with Liver Metastases from Breast Cancer (2006) (23)
Reverse phase protein array based tumor profiling identifies a biomarker signature for risk classification of hormone receptor-positive breast cancer (2014) (23)
IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC). (2016) (23)
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus (2015) (23)
Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry (2017) (23)
Do Patients After Reexcision Due to Involved or Close Margins Have the Same Risk of Local Recurrence as Those After One-Step Breast-Conserving Surgery? (2016) (23)
A complex nursing intervention of complementary and alternative medicine (CAM) to increase quality of life in patients with breast and gynecologic cancer undergoing chemotherapy: study protocol for a partially randomized patient preference trial (2015) (23)
Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. (2021) (23)
Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. (2020) (23)
Abstract PD1-02: Cancer predisposition genes in metastatic breast cancer – Association with metastatic pattern, prognosis, patient and tumor characteristics (2018) (22)
Update Breast Cancer 2017 – Implementation of Novel Therapies (2017) (22)
Breast Cancer Mastectomy Trends Between 2006 and 2010: Association with Magnetic Resonance Imaging, Immediate Breast Reconstruction, and Hospital Volume (2013) (22)
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients (2017) (22)
Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence. (2017) (22)
S2-4: GAIN Study: A Phase III Trial To Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients with Node-Positive Primary Breast Cancer – 1st Interim Efficacy Analysis. (2011) (22)
Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice (2019) (22)
Clinical relevance and concordance of HER2 status in local and central testing—an analysis of 1581 HER2-positive breast carcinomas over 12 years (2017) (22)
End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). (2019) (22)
Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis. (2021) (22)
Effects of physical exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy (2018) (21)
Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69 (2018) (21)
Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer (2016) (21)
Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers (2018) (21)
Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System (2010) (21)
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. (2021) (21)
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer (2012) (21)
Abstract P5-18-26: Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC) (2012) (21)
Circulating tumor cells (CTCs) in peripheral blood of primary breast cancer patients (2007) (21)
Time trends in axilla management among early breast cancer patients: Persisting major variation in clinical practice across European centers (2016) (21)
Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice? (2018) (20)
Evaluation of Promoter Methylation of RASSF1A and ATM in Peripheral Blood of Breast Cancer Patients and Healthy Control Individuals (2018) (20)
LBA9BREAST CANCER TREATMENT WITH EVEROLIMUS AND EXEMESTANE FOR ER+ WOMEN - RESULTS OF THE 2ND INTERIM ANALYSIS OF THE NON-INTERVENTIONAL TRIAL BRAWO (2014) (20)
An evaluation of a transcutaneous and an end-tidal capnometer for noninvasive monitoring of spontaneously breathing patients. (2006) (20)
Targeted next‐generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance (2017) (20)
An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study (2019) (20)
Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer (2019) (20)
Therapeutic effects of metformin in breast cancer: involvement of the immune system? (2011) (20)
Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk (2011) (20)
A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin / cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA. (2016) (19)
CD24 polymorphisms in breast cancer: impact on prognosis and risk (2013) (19)
Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma – What is the Role of Liquid Biopsy in Breast Cancer? (2017) (19)
Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy (2018) (18)
Update Breast Cancer 2020 Part 1 – Early Breast Cancer: Consolidation of Knowledge About Known Therapies (2020) (18)
Abstract PD1-07: Exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: A retrospective substudy of IMpassion130 (2020) (18)
The BRCA2 c.68‐7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity (2018) (18)
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. (2021) (18)
Chemotherapy for Metastatic Breast Cancer – An Anachronism in the Era of Personalised and Targeted Oncological Therapy? (2015) (18)
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022 (2022) (18)
Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer. (2009) (18)
Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signature. (2014) (18)
Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923). (2018) (18)
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. (2016) (18)
Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer (2020) (18)
Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients (2018) (18)
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer. (2011) (18)
Carcinoma of Unknown Primary – an Orphan Disease? (2008) (18)
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer (2021) (18)
Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer (2019) (17)
The effects of an integrated supportive care intervention on quality of life outcomes in outpatients with breast and gynecologic cancer undergoing chemotherapy: Results from a randomized controlled trial (2019) (17)
Update Breast Cancer 2019 Part 1 – Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer (2019) (17)
Abstract GS5-03: Lifestyle Intervention and Effect on Disease-free Survival in Early Breast Cancer Pts: Interim Analysis from the Randomized SUCCESS C Study (2019) (17)
Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer (2020) (17)
Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study. (2008) (17)
163PDLong-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto) (2017) (17)
Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer (2006) (17)
Time trends of neoadjuvant chemotherapy for early breast cancer (2020) (17)
Irrigation fluid absorption during transurethral resection of the prostate: Spinal vs. general anaesthesia (1999) (17)
Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study (2014) (16)
Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study. (2017) (16)
S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer. (2015) (16)
Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69) (2017) (16)
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto (2019) (16)
Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence (2017) (16)
Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer (1999) (16)
Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET Pathway (2016) (15)
Completion rate and impact on physician–patient relationship of video consultations in medical oncology: a randomised controlled open-label trial (2020) (15)
Abstract S2-03: Persistence of circulating tumor cells in high risk early breast cancer patients during follow-up care suggests poor prognosis – Results from the adjuvant SUCCESS A trial (2016) (15)
Adjuvante simultane Mistel-/Chemotherapie bei Mammakarzinom – Einfluss auf Immunparameter, Lebensqualität und Verträglichkeit (2008) (15)
Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials. (2015) (15)
Abstract S5-05: Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxane-based chemotherapy for primary breast cancer – The phase III NATAN study (GBG 36/ABCSG XX) (2013) (15)
Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer. (2009) (15)
Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study (2014) (15)
Abstract PD3-12: Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - results from the randomized phase III DETECT III trial (2021) (15)
HER2-targeted therapy influences CTC status in metastatic breast cancer (2020) (15)
Translational highlights in breast cancer research and treatment: recent developments with clinical impact (2019) (15)
Abstract GS1-10: Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE (2019) (15)
Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation (2002) (15)
Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium (2021) (14)
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. (2021) (14)
Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. (2014) (14)
Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer (2020) (14)
Nab-Paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice. (2013) (14)
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. (2016) (14)
Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy. (2001) (14)
Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications (2017) (14)
A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). (2015) (14)
Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics (2020) (13)
Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment (2018) (13)
437 A multicenter phase II trial to evaluate gefitinib (‘Iressa’, ZD1839) (500 mg/day) in patients with metastatic breast cancer after previous chemotherapy treatment (2003) (13)
Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment (2016) (13)
Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy (2019) (13)
Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A- trial (2016) (13)
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2‐negative, Hormone Receptor‐positive Early Breast Cancer (2017) (13)
DETECT III: A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients (pts) with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumor cells (CTC). (2012) (13)
Abstract GS1-06: Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study (2018) (13)
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). (2017) (13)
296P Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial (2020) (13)
1816 Preliminary safety results from PERUSE, a study of 1436 patients (pts) treated with first-line pertuzumab (P) combined with trastuzumab (H) and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC) (2015) (13)
Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839). (2004) (12)
Maintenance of epithelial traits and resistance to mesenchymal reprogramming promote proliferation in metastatic breast cancer (2020) (12)
In silico SNP analysis of the breast cancer antigen NY-BR-1 (2016) (12)
Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial (2020) (12)
Non-pegylated liposomal doxorubicin for patients with recurrent ovarian cancer: A multicentric phase II trial. (2016) (12)
Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer (2018) (12)
Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer (2020) (12)
Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. (2017) (12)
Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial (2005) (12)
Plasma S100P level as a novel prognostic marker of metastatic breast cancer (2016) (12)
Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose. (2002) (12)
Abstract P5-15-03: nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial (2017) (12)
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC (2020) (12)
88MO T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer (2020) (12)
Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives (2018) (12)
Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011) (2011) (12)
Abstract S4-06: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer – Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies (2013) (12)
Protein phosphatase 1, regulatory subunit 15B is a survival factor for ERα‐positive breast cancer (2013) (11)
CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer (2021) (11)
Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: Long‐term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials (2013) (11)
Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer (2020) (11)
Abstract OT1-1-02: A single-arm phase IIIb study of pertuzumab and trastuzumab with a taxane as first-line therapy for patients with HER2-positive advanced breast cancer (PERUSE) (2012) (11)
317TiPIMpassion131: Phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC) (2017) (11)
Generalized Lichen Ruber Planus – Induced by Radiotherapy of the Breast? (2006) (11)
Stem Cell Dose and Tumorbiologic Parameters as Prognostic Markers for Patients with Metastatic Breast Cancer Undergoing High‐Dose Chemotherapy with Autologous Blood Stem Cell Support (2002) (11)
AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update (2021) (11)
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. (2021) (11)
[Adjuvant simultaneous mistletoe chemotherapy in breast cancer--influence on immunological parameters, quality of life and tolerability]. (2008) (11)
Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient (2018) (11)
Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial. (2019) (11)
Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation (2019) (11)
Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial (2021) (11)
Adjuvant Intensity Modulated Whole-Abdominal Radiation Therapy for High-Risk Patients With Ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): First Results of a Prospective Phase 2 Study. (2017) (11)
Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers (2013) (11)
Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC). (2018) (11)
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial (2020) (11)
Update Breast Cancer 2020 Part 3 – Early Breast Cancer (2020) (10)
IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). (2018) (10)
Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials. (2021) (10)
First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study. (2016) (10)
The role of neoadjuvant chemotherapy in the management of primary breast cancer. (2011) (10)
Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer (2018) (10)
Abstract PD2-07: mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)– Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial (2019) (10)
Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer (2020) (10)
Abstract OT1-01-06: A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC) (2016) (10)
Divergent Patterns and Trends in Breast Cancer Incidence, Mortality and Survival Among Older Women in Germany and the United States (2020) (9)
Effects of distant metastasis and peripheral CA 15-3 on the induction of spontaneous T cell responses in breast cancer patients (2010) (9)
Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy – German Experts’ Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019) (2019) (9)
pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. (2017) (9)
World Congress Integrative Medicine & Health 2017: part two (2017) (9)
Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial. (2016) (9)
T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. (2015) (9)
Abstract P2-08-01: Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy – Results of a pooled analysis based on the GBG meta-database (2019) (9)
Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study (2019) (9)
Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective (2014) (9)
Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer (1998) (9)
Abstract P3-11-07: Factors associated with first line chemotherapy use in patients with hormone receptor positive, HER2 negative metastatic breast cancer – data from the PRAEGNANT breast cancer registry (2018) (9)
Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer (2018) (9)
Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer (2015) (9)
Abstract OT3-3-11: A RANDOMIZED PHASE III TRIAL COMPARING NANOPARTICLE-BASED PACLITAXEL WITH SOLVENT-BASED PACLITAXEL AS PART OF NEOADJUVANT CHEMOTHERAPY FOR PATIENTS WITH EARLY BREAST CANCER (GeparSepto) GBG 69 (2012) (9)
Impact in delay of starting chemotherapy and surgery on pCR/survival in breast cancer (BC)-pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials (2017) (9)
Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes (2019) (9)
455 A phase II study of first-line combination chemotherapy with docetaxel and gemcitabine in anthracycline-pretreated, Her-2 negative metastatic breast cancer (MBC) (2003) (9)
Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry (2017) (9)
Predictors of Residual Tumor in Breast-Conserving Therapy (2015) (9)
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy (2019) (8)
Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial (2016) (8)
328TiP Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09 (2021) (8)
First-line pertuzumab (P), trastuzumab (H), and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC): Interim safety results (N=704) from PERUSE. (2014) (8)
Abstract OT2-06-01: Highly innovative personalized RNA-immunotherapy for patients with triple negative breast cancer (2019) (8)
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast (2021) (8)
Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial (2022) (8)
Prognostic value of HER2 on breast cancer survival. (2013) (8)
Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance (2014) (8)
Smaller regional volumes of gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy (2007) (8)
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study (2018) (8)
The coming decade in precision oncology: six riddles (2022) (7)
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C (2022) (7)
Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients (2006) (7)
Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study. (2019) (7)
Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment. (2011) (7)
Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry. (2017) (7)
Chromothripsis in Human Breast Cancer (2020) (7)
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial. (2021) (7)
No Clinical Evidence for Increase in Tumour Malignant Potential in Patients (Pts) with Metastatic Breast Cancer (mBC) Treated with Bevacizumab (BV) and Docetaxel (D) in the Phase III AVADO Study. (2009) (7)
Adjuvant gemcitabine for high-risk breast cancer (BC) patients: Final survival results of the randomized phase III SUCCESS-A study. (2014) (7)
Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells (2019) (7)
Abstract OT1-03-02: MP0274-CP101: A phase 1, first-in-human, single-arm, multi-center, open-label, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors (2018) (7)
How the Consolidated Framework for Implementation Research Can Strengthen Findings and Improve Translation of Research Into Practice: A Case Study. (2017) (7)
Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy (2022) (7)
Long-term remission of excessive liver metastases in a breast cancer patient with chronic alcohol abuse using a monotherapy with trastuzumab. (2005) (6)
Impact of symptoms and toxicity on quality of life: Exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. (2006) (6)
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT (2022) (6)
Chemotherapy with carboplatin/docetaxel for primary and recurrent epithelial ovarian cancer (2001) (6)
P2-12-26: Impact of the Recurrence Score on Adjuvant Decision-Making in ER-Positive Early Breast Cancer – Results of a Large Prospective Multicentre Decision Impact Study in Node Negative and Node Positive Disease. (2011) (6)
Abstract GS3-01: Investigating denosumab as an add-on treatment to neoadjuvant chemotherapy and two different nab-paclitaxel schedules in a 2x2 design in primary breast cancer - First results of the GeparX study (2020) (6)
Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer (2022) (6)
Prognostic markers for survival after high-dose chemotherapy with autologous stem-cell transplantation for breast cancer. (2003) (6)
Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy – translational research program of the German SUCCESS-trial. (2009) (6)
Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (2018) (6)
The DETECT study concept: Individualized therapy of metastatic breast cancer. (2016) (6)
Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. (2021) (6)
Neoadjuvant therapy with gemcitabine in breast cancer. (2004) (6)
Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients (2021) (6)
Abstract P5-19-06: 4EVER - Final efficacy analysis of the phase IIIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE) (2015) (6)
Circulating microRNAs as Surrogate Markers for Circulating Tumour Cells and Prognostic Markers in Metastatic Breast Cancer (2012) (6)
Abstract P6-11-10: Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry (2018) (6)
Abstract 4699: Responsecharacteristics and overall survival of 781 patients with triple-negativebreast cancer - a meta-analysis on 7 German neoadjuvant studies. (2013) (6)
Biomarker (BM) Analyses of a Phase II Study of Neoadjuvant Pertuzumab and Trastuzumab With and Without Anthracycline (ATC)-Containing Chemotherapy for Treatment of HER2-Positive Early Breast Cancer (BC) (Tryphaena) (2012) (6)
Abstract P5-19-07: Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-Breast 3 (2015) (6)
Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial (2016) (6)
Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element (2021) (6)
Practical experiences with eribulin in patients with metastatic breast cancer (2016) (6)
CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients (2016) (6)
German Adjuvant Intergroup Node Positive (GAIN) study: A phase III trial to compare IDD-ETC versus EC-TX in patients with node-positive primary breast cancer—Final efficacy analysis. (2014) (6)
Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. (2019) (6)
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab (2020) (6)
Utility of the CPS+EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy (2019) (6)
Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients – a Survey Among Physicians (2018) (5)
1805 Association between HER2-phenotype on circulating tumor cells and primary tumor characteristics in women with metastatic breast cancer (2015) (5)
Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers (2021) (5)
Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: Pooled analysis based on the GBG database. (2019) (5)
Update Breast Cancer 2021 Part 4 – Prevention and Early Stages (2022) (5)
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. (2022) (5)
Abstract PD5-08: Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - An analysis of the GeparSepto trial (2020) (5)
Update Breast Cancer 2021 Part 1 – Prevention and Early Stages (2021) (5)
Predictors of resectability in breast-conserving therapy (2012) (5)
Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus (2021) (5)
Amplification and expression of the c-erbB-2 oncogene in Müllerian-derived genital-tract tumors. (1998) (5)
AGO Algorithms for the Treatment of Breast Cancer: Update 2021 (2021) (5)
Tumor infiltrating lymphocytes before and after dual HER2 blockade in HER2-amplified early breast cancer: A TRYPHAENA substudy. (2016) (5)
Frequent Molecular Subtype Switching and Gene Expression Alterations in Lung and Pleural Metastasis From Luminal A–Type Breast Cancer (2020) (5)
Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. (2021) (5)
ABC1 Consensus Conference – a German Perspective (2012) (5)
Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial. (2007) (5)
0157 GAIN study: A phase III trial to compare ETC vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer (2009) (5)
Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC). (2019) (5)
Prediction of local recurrence risk after neoadjuvant chemotherapy in patients with primary breast cancer: Clinical utility of the MD Anderson Prognostic Index (2019) (5)
Abstract P5-21-09: Overall survival of metastatic breast cancer patients – data from the PRAEGNANT breast cancer registry (2018) (5)
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer) (2009) (5)
Ileouterine fistula after primary treatment of advanced endometrial cancer. (2006) (5)
Abstract P5-19-12: Subgroup analysis on efficacy in the routine treatment - Results of the 2nd interim analysis of BRAWO, the non-interventional trial "Breast Cancer Treatment with Everolimus and Exemestane for HR+ Women" (2015) (5)
Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer (2016) (5)
Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993. (2021) (5)
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy. (2021) (5)
Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS+EG score (2019) (5)
Abstract P1-09-02: Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer (2017) (5)
Abstract P6-17-22: Progression free survival (PFS) and overall survival (OS) of patients treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab in patients with advanced breast cancer (NCT02338167) (2019) (5)
2O Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial (2021) (5)
Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. (2019) (4)
Persistence of HER2 overexpression on circulating tumor cells in patients after systemic treatment for HER2-positive breast cancer: Follow-up results of the German Success B trial. (2013) (4)
Neoadjuvant and adjuvant end-points in health technology assessment in oncology. (2021) (4)
Abstract OT1-01-01: IMpassion131: A phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC) (2018) (4)
Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer (2022) (4)
FGFR 4 Arg 388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer (2010) (4)
Abstract P4-13-06: Results of the 3rd interim analysis of the non-interventional trial BRAWO – Subanalysis of patients <70 years and ≥ 70 years (2016) (4)
267PCan contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit? (2017) (4)
329TiP KATE3: A phase III study of trastuzumab emtansine (T-DM1) in combination with atezolizumab or placebo in patients with previously treated HER2-positive and PD-L1–positive locally advanced or metastatic breast cancer (2021) (4)
Incorporating progesterone receptor expression into the PREDICT breast prognostic model. (2022) (4)
Identification of NY‐BR‐1‐specific CD4+ T cell epitopes using HLA‐transgenic mice (2015) (4)
Catumaxomab with and without prednisolone in patients with malignant ascites due to epithelial cancer: Results from the phase IIIb CASIMAS study. (2012) (4)
Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer (2018) (4)
Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis—Results from the Adjuvant SUCCESS A Trial (2022) (4)
Chemotherapy-induced peripheral neuropathy: longitudinal analysis of predictors for postural control (2021) (4)
Comparison of Double and Triple High‐Dose Chemotherapy with Autologous Blood Stem Cell Transplantation in Patients with Metastatic Breast Cancer (2001) (4)
Neoadjuvant chemotherapy for patients with breast cancer during pregnancy (BCP). (2014) (4)
Bevacizumab in the Treatment of Metastatic Breast Cancer (2007) (4)
Activity and Tolerability of a Combined Palliative Chemotherapy With Mitomycin C, Folinate, and 5-Fluorouracil in Patients With Advanced Breast Cancer After Intensive Pretreatment: A Retrospective Analysis (2007) (4)
The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer (2020) (4)
L-Thyroxine intake as a potential risk factor for the development of fatigue in breast cancer patients undergoing chemotherapy (2018) (4)
Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity. (2017) (4)
Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) (2012) (4)
Öffentliches Baurecht praxisnah (2012) (4)
Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer (2022) (4)
SERAPHINA – Safety, Efficacy and patient Reported outcomes of Advanced breast cancer Patients: tHerapy management wIth NAb-paclitaxel in daily routine (a non-interventional study) (2016) (4)
Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients (2011) (4)
Impact of reproductive factors on breast cancer subtypes in postmenopausal women: a retrospective single-center study (2017) (4)
Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer (1999) (4)
Änderungen der Stadiengruppierung und Überlebensraten bei Anwendung der neuen TNM-Klassifikation für das Mammakarzinom (2004) (4)
Genetic variation at CYP 3 A is associated with age at menarche and breast cancer risk : a case-control study (2014) (4)
AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022 (2022) (4)
49MO IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer (2020) (4)
Do patients with invasive lobular breast cancer benefit in terms of adequate change in surgical therapy from a supplementary preoperative breast MRI? (2012) (4)
First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study (2021) (4)
Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2- breast cancer. (2017) (4)
Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer (2020) (4)
Breast cancer presentation and therapy in migrant versus native German patients: contrasting and convergent data of a retrospective monocentric study (2016) (3)
Biomarker für Patientinnen mit metastasiertem Mammakarzinom und das PRAEGNANT-Studiennetzwerk (2015) (3)
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). (2021) (3)
Dose dense gemcitabine/epirubicin (GE) followed sequentially by dose dense docetaxel (Doc) as primary systemic therapy (PST) of patients (pts) with early breast cancer (BC): First results of a phase I/II trial. (2004) (3)
Comparison of immunohistological parameters in primary breast cancers and corresponding locoregional recurrences. (2006) (3)
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. (2019) (3)
Abstract P5-16-01: A randomised phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto) (2017) (3)
Validation of Nine Different Prognostic Grading Indexes for Radiosurgery of Brain Metastases in Breast Cancer Patients and Development of an All-Encompassing Prognostic Tool (2020) (3)
Bendamustine hydrochloride - a renaissance of alkylating strategies in anticancer medicine. (2009) (3)
191 DETECT III – a Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells (2012) (3)
Hirnmetastasierung bei Patientinnen mit Mammakarzinom nach einer neoadjuvanten Chemotherapie (2018) (3)
Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel (Pac): An observational study in 786 patients (pts) with HER2-negative metastatic breast cancer (mBC). (2011) (3)
[Metastatic breast cancer in the spine : Molecular predictors for choosing adequate treatment strategies]. (2018) (3)
Targeted Therapy of HER2-Negative Breast Cancer (2016) (3)
Abstract P4-21-04: Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (PERUSE) (2017) (3)
Abstract P4-21-02: Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA) (2017) (3)
Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries (2019) (3)
Abstract PD2-2: Body mass index (BMI) and treatment outcome of breast cancer patients receiving neoadjuvant therapy (NACT) (2013) (3)
Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine (2020) (3)
Germline BRCA1and BRCA2 mutations in patients with HER2-negative metastatic breast cancer (mBC) treated with first-line chemotherapy: Data from the German PRAEGNANT registry. (2019) (3)
Supportive therapy with epoetin-alpha in breast cancer patients (pts) receiving dose-dense sequential chemotherapy with epirubicin, paclitaxel and cyclophosphamide (ETC) (2001) (3)
The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial (2018) (3)
Abstract P1-18-01: Risk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response (pCR) after different types of HER2-targeted therapy: A retrospective exploratory analysis (2020) (3)
Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting. (2018) (3)
Abstract P3-06-08: Ki-67 mRNA as a predictor for response to neoadjuvant chemotherapy in primary breast cancer (2012) (3)
St.-Gallen-Konferenz 2011 zum primären Mammakarzinom (2011) (3)
P176 The DETECT-study concept – circulating tumor cells (CTCs) in metastatic breast cancer (2015) (3)
Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment (2021) (3)
Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344). (2019) (3)
Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls. (2021) (3)
Abstract OT1-10-01: DETECT III/IV study trial – The multicenter study program in patients with HER2-negative metastatic breast cancer and circulating tumor cells (2019) (3)
Zervixkarzinom in der Schwangerschaft (2018) (3)
4EVER: Assessment of circulating tumor cells with a novel, filtration-based method, in a phase IIIb multicenter study for postmenopausal, HER2- negative, estrogen receptor-positive, advanced breast cancer patients. (2013) (3)
Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk (2020) (3)
Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC) (2019) (3)
Efficacy and Safety of First-Line Bevacizumab (BEV) Combined with Paclitaxel (PAC) According to Age: Subpopulation Analysis of a Large, Multicenter, Non-Interventional Study in Patients (Pts) with HER2-Negative Metastatic Breast Cancer (MBC). (2009) (3)
The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features (2015) (3)
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis (2022) (2)
Intense dose-dense (idd) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (ETC) compared with conventionally scheduled chemotherapy in high-risk breast cancer patients (> 3+LN): Eight-year follow-up analysis. (2011) (2)
Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer (2021) (2)
BRCA1 like copy number profiles to predict benefit of intensified alkylating chemotherapy in breast cancer (2013) (2)
HER2 expression on circulating tumor cells (CTC) in patients with early HER2-positive breast cancer: Results of the German SUCCESS B trial. (2012) (2)
The DETECT Study Program: Personalized treatment in advanced breast cancer based on circulating tumor cells (CTCs). (2015) (2)
Correction: Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer (2022) (2)
199TiP Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA (2021) (2)
Endoscopic stenting of the common bile duct allows successful treatment of a breast cancer patient with excessive liver metastases. (2004) (2)
Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer: A genome-based investigation in the neoadjuvant GeparSepto trial. (2018) (2)
Klinische Endpunkte in Real-World-Register-Studien (2020) (2)
IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC). (2019) (2)
Parity improves anti-tumor immunity in breast cancer patients (2017) (2)
Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Breast Cancer (Zurich 2011) (2011) (2)
11th International Conference St. Gallen: Primary Therapy of Early Breast Cancer (2009) (2)
Update Mammakarzinom 2020 Teil 2 – fortgeschrittenes Mammakarzinom: neue Substanzen und Einzug diagnostikabhängiger Therapien (2020) (2)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben. Berlin, 21.-24. Februar 2018: Abstracts (2018) (2)
The PACOVAR-trial: A multicenter phase I trial of pazopanib (GW786034) and metronomic cyclophosphamide in patients with recurrent platinum-resistant ovarian cancer. (2015) (2)
168MO GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status (2020) (2)
Abstract OT1-02-04: The DETECT V-study – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer (2017) (2)
Auswirkung von G-CSF auf zirkulierende Tumorzellen (CTC) und CA27.29 bei Patientinnen mit Mammakarzinom (2009) (2)
Abstract P6-18-08: Everolimus + exemestane for HR+ advanced breast cancer in routine clinical practice- Final results from the non-interventional trial, BRAWO (2019) (2)
Molecular and clinical characterization of an in frame deletion of uncertain clinical significance in the BRCA2 gene (2012) (2)
Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial. (2019) (2)
AGO Recommendations for the Diagnosis and Therapy of Breast Cancer (2007) (2)
Fine-mapping identi fi es two additional breast cancer susceptibility loci at 9 q 31 . 2 (2015) (2)
Association of the fibroblast growth factor receptor-4 (FGFR4) Gly388Arg polymorphism with clinical and pathological response to primary systemic therapy (PST) for early breast cancer (EBC). (2016) (2)
AGO-Empfehlungen zur operativen Therapie des Mammakarzinoms: Update 2022 (2022) (2)
A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4673 (durvalumab) to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (GeparNuevo) (2016) (2)
O-49 A phase III trial of Gemcitabine plus Docetaxel (GD) versus Capecitabine plus Docetaxel (CD) for patients (pt) with anthracycline-pretreated metastatic breast cancer (2007) (2)
Update Mammakarzinom 2019 Teil 5 – diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien bei Patientinnen mit fortgeschrittenem Mammakarzinom (2019) (2)
Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC). (2018) (2)
Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity (2017) (2)
Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2). (2013) (2)
Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment (2022) (2)
rs2735383, located at a microRNA binding site in the 3’UTR of NBS1, is not associated with breast cancer risk (2016) (2)
Combined Chemotherapy with Mitomycin C, Folinic Acid, and 5-Fluorouracil (MiFoFU) as Salvage Treatment for Patients with Liver Metastases from Breast Cancer – a Retrospective Analysis (2008) (2)
Biomarkers for response to immunotherapy in triple-negative breast cancer: Differences between survival and pCR biomarkers. (2022) (2)
BRCA1 like copy number profiles to predict benefit of intensified alkylating chemotherapy in breast cancer. (2013) (2)
Investigating denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-paclitaxel schedules: 2x2 factorial design (GeparX)—An iterim safety analysis. (2018) (2)
5073 POSTER Bevacizumab (Bev) Combined With Paclitaxel (Pac) as First-line Therapy for Metastatic Triple-negative Breast Cancer (TNBC) -Analysis of 147 Patients (pts) Treated in Routine Oncology Practice in Germany (2011) (2)
Abstract P3-06-19: Ki-67 mRNA as a predictor for response to neoadjuvant chemotherapy in primary breast cancer (2012) (2)
Abstract P6-11-13: Phase Ib study evaluating the safety and clinical activity of lumretuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer (2017) (2)
Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study (2021) (2)
Comparison of therapy benefit from standard anti-HER2-directed approaches in metastatic breast cancer (MBC) between initially-HER2 positive patients and patients initially HER2-negative with switch to HER2-positive (2021) (2)
Safety of surgery in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) treated with docetaxel (D) plus bevacizumab (BV) or placebo (PL) in the AVADO phase III study. (2009) (2)
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy (NACT) for early breast cancer: Three-year follow-up data. (2012) (2)
176P Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332) (2020) (2)
Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX). (2016) (2)
Intrinsic subtypes and risk scores in ER+/HER2-Breast Cancer: a comparison of Prosigna and OncotypeDX risk categories with Ki67 (2017) (2)
COOLHAIR: A prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing neoadjuvant chemotherapy for early breast cancer. (2017) (2)
Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC). (2017) (2)
Abstract P1-13-05: GAIN-2: Adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results of the second safety interim analyses (2016) (2)
160O Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC) (2020) (2)
Real-world effectiveness and safety of first-line bevacizumab (BEV) + paclitaxel (PAC) in >2000 patients (pts) with HER2-negative metastatic breast cancer (mBC) (2016) (2)
CXCR3-expressing metastasis-initiating cells induce and exploit a fibroblast niche in the lungs to fuel metastatic colonization (2019) (2)
Analysis according to prognostic factors in patients (pts) treated with first-line bevacizumab (BEV) combined with paclitaxel (PAC) for HER2-negative metastatic breast cancer (mBC) in a routine oncology practice study. (2012) (2)
Gene expression profiles predict pathologic complete response to preoperative chemotherapy with gemcitabine, epirubicin and docetaxel in primary breast cancer (2005) (2)
Das Südwestdeutsche Brustcentrum (SWBC) Heidelberg – ein Netzwerk zur Qualitätssteigerung in der Diagnostik und Therapie des Mammakarzinoms (2006) (2)
Abstract P4-13-08: Stomatitis in patients treated with everolimus and exemestane - Results of the 3rd interim analysis of the non-interventional trial BRAWO (2016) (2)
GAIN-2: Neo-/adjuvant phase III trial to compare intense dose-dense chemotherapy (CT) to tailored dose-dense CT in patients (pts) with high risk early breast cancer (EBC): Results on safety and interim invasive disease-free survival (iDFS). (2020) (2)
Abstract P4-14-04: AVANTI: A non-interventional study examining the combination of bevacizumab with paclitaxel or capecitabine in metastatic breast cancer (2013) (1)
Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A- trial (2016) (1)
[Systemic therapy of operable carcinoma of the breast]. (2005) (1)
Abstract PD13-10: PD13-10 Impact of Proton Pump Inhibitors (PPI) on Palbociclib (PAL) Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (HR+/HER2- ABC): Exploratory Analysis of the PARSIFAL Trial (2023) (1)
Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit? (2018) (1)
Abstract P4-21-07: Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy in patients ≥65 years with HER2-positive locally recurrent/metastatic breast cancer: Subgroup analyses of the PERUSE study (2017) (1)
DNA methylation array analyses to identify HYAL2 methylation in peripheral blood as a marker for the detection of early breast cancer. (2014) (1)
5145 Success-C-study: simultaneous study of docetaxel based anthracycline free adjuvant treatment evaluation as well as life style intervention strategies (2009) (1)
Induction Therapy for Acute Myelogenous Leukemia with Idarubicin/Cytosine Arabinoside and Mitoxantrone/Etoposide in “Response-Adapted” Sequence (1992) (1)
Abstract PD18-07: Omission of chemotherapy in the treatment of HER2-positive and hormone-receptor positive metastatic breast cancer – interim results from the randomized phase 3 DETECT V trial (2023) (1)
Stereotactic radiosurgery for brain metastases from pelvic gynecological malignancies: oncologic outcomes, validation of prognostic scores, and dosimetric evaluation (2021) (1)
Gene Expression Profiling to Predict Chemotherapy Response in Primary Breast Cancer (2006) (1)
OT1-02-06: DETECT III – A Multicenter, Randomized, Phase III Study To Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2−Negative Metastatic Breast Cancer and HER2−Positive Circulating Tumor Cells. (2011) (1)
Catumaxomab versus catumaxomab plus prednisolone in patients with malignant ascites due to epithelial cancer: results from the CASIMAS study (2012) (1)
Cellular immunotherapy in late stage breast cancer patients with reactivated autologous Memory T-cells (MTC) derived from bone marrow (BM). (2004) (1)
28 Stress signalling in breast cancer cells induces matrix components of stem cell niches that promote chemotherapy-resistant metastasis (2018) (1)
[Magnetic resonance tomographic imaging of bone marrow involvement in angioimmunoblastic lymphadenopathy]. (1990) (1)
1552O Chemotherapy-induced peripheral neuropathy (CIPN) prevention trial evaluating the efficacy of hand-cooling and compression in patients undergoing taxan-based (neo-)adjuvant chemotherapy for primary breast cancer: First results of the prospective, randomized POLAR trial (2022) (1)
Abstract OT2-01-18: RIBECCA - A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole (2017) (1)
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients (2015) (1)
4265 Pegfilgrastim on day 2 vs. day 4 within the prospective, multi- centered GAIN study: A phase III trial to compare ETC vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer (GBG 33) (2009) (1)
Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials (2019) (1)
Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Breast Cancer Patients. (2022) (1)
Abstract P1-17-01: Development of brain metastases in breast cancer patients treated in the neoadjuvant trials Geparquinto and Geparsixto (2018) (1)
Abstract 5010: Prediction of therapy resistance by targeted massive-parallel sequencing in primary HER2-positive breast cancer (2016) (1)
Abstract P3-07-03:PIK3CAmutations predict resistance to trastuzumab/pertuzumab andnab-paclitaxel in primary HER2-positive breast cancer – Massive parallel sequencing analysis of 293 pretherapeutic core biopsies of the GeparSepto study (2016) (1)
Evaluation of prevalence, number, and temporal changes of circulating tumor cells as assessed after 2 and 5 years of follow-up in patients with early breast cancer in the SUCCESS A study. (2013) (1)
Pertuzumab in Combination with Trastuzumab and a Taxane for the First-Line Treatment of Patients with HER2-Positive Advanced Breast Cancer: A Single Arm Phase IIIB Study (Peruse) (2012) (1)
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients (2022) (1)
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial (2015) (1)
Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer (2022) (1)
Tumor infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: A TRYPHAENA substudy (2018) (1)
Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study (2019) (1)
Quality of life measurement in breast cancer patients: Reliability of an ePRO tool using EORTC QLQ-C30 (2019) (1)
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial (2022) (1)
Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer. (2022) (1)
Abstract P3-10-20: The Prognostic Relevance of Serum CA27.29 level in Primary Breast Cancer Patients before Adjuvant Chemotherapy — Results of the German SUCCESS Trial (2010) (1)
264PDGAIN2: ADJUVANT PHASE III TRIAL COMPARING AN INTENSIFIED DOSE-DENSE ADJUVANT THERAPY WITH ENPC COMPARED WITH A DOSE-DENSE, DOSE-ADAPTED THERAPY WITH DTEC DTDOCETAXEL IN PATIENTS WITH PRIMARY BREAST CANCER AND A HIGH RISK OF RECURRENCE. (2014) (1)
445 Characteristics of patients with long-term survival after occurrence of liver metastases from breast cancer (2003) (1)
Abstract P2-05-02: Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent prognosis (2017) (1)
Preoperative Systemic Treatment in BRCA-Positive Breast Cancer Patients: Case Report and Review of the Literature (2011) (1)
Abstract PD10-05: Activity of atezolizumab (atezo) plus paclitaxel (pac) in metastatic triple-negative breast cancer (mTNBC) according to Burstein molecular subtype: Analysis of the IMpassion131 trial (2022) (1)
Abstract OT1-02-02: The DETECT study program – Personalized treatment in metastatic breast cancer based on circulating tumor cells (2016) (1)
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany (2020) (1)
The SUCCESS-C trial: Interim analysis of toxicity evaluating the role of an anthracycline-free chemotherapy regimen in the adjuvant treatment of HER2/neu-negative breast cancer. (2011) (1)
301 Survival in Early Breast Cancer Patients is Influenced by Circulating Tumor Cells (2012) (1)
194 Tandem high dose chemotherapy with peripheral blood stem cell support (PBSCS) in limited stage small cell lung cancer (SCLC) (1997) (1)
Abstract P4-13-26: Efficacy, safety, and treatment decision-making in the AVANTI German observational study of first-line bevacizumab (BEV)-containing therapy for locally advanced, recurrent, or metastatic breast cancer (aBC) (2016) (1)
Cellular immunotherapy in late stage breast cancer patients with reactivated autologous Memory T-cells derived from bone marrow (2005) (1)
How previous treatment changes the metabolomic profile in patients with metastatic breast cancer (2022) (1)
Initial Treatment of Patients with Primary Breast Cancer : Evidence , Controversies , Consensus Spectrum of Opinion of German Specialists at the 15 th International (2017) (1)
Abstract P5-06-02: Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC) (2020) (1)
127O Tumour mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo (2020) (1)
Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study. (2018) (1)
Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial (2019) (1)
Abstract PD9-04: Immunological and clinical consequences of durvalumab treatment in combination to neoadjuvant chemotherapy in triple-negative breast cancer patients (2023) (1)
Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy. (2004) (1)
Abstract P2-08-10: Similarities between low hormone receptor positive and hormone receptor negative breast cancer: An analysis of 4366 patients from multicenter clinical trials (2019) (1)
Abstract P3-11-05: Reliability and acceptance of e-based survey instruments for measuring patient reported outcomes (PRO) in breast cancer patients: First results of the ePROCOM study (2017) (1)
Abstract PD5-05: Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial (2019) (1)
255ODUAL BLOCKADE WITH AFATINIB AND TRASTUZUMAB AS NEOADJUVANT TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR OPERABLE BREAST CANCER RECEIVING TAXANE-ANTHRACYCLINE CONTAINING CHEMOTHERAPY (DAFNE)-GBG70 - EFFICACY AND SAFETY ANALYSIS. (2014) (1)
Abstract P2-01-02: Circulating Tumor Cells (CTC) may Express HER2/neu in Patients With Early HER2/neu Negative Breast Cancer – Results of the German SUCCESS C Trial (2012) (1)
Correlation of high body mass index and circulating tumor cell positivity in patients with early-stage breast cancer. (2012) (1)
Does a treatment with Viscum album (Iscador® P) in patients with breast cancer influence the expression of the T-cell receptor (TCR)-zeta chains of T- and NK-cells? (2011) (1)
Abstract PS10-31: Ribecca - a phase 3b, multi-center, open label study for women with estrogen receptor positive, locally advanced or metastatic breast cancer treated with ribociclib (lee011) in combination with letrozole: Final results (2021) (1)
Cellular immunotherapy in late stage breast cancer patients with reactivated autologous Memory T-cells (MTC) derived from bone marrow (BM) (2004) (1)
Expression of SPARC and response to nab-paclitaxel (nab-p) in patients (pts) with metastatic breast cancer (MBC). (2014) (1)
Abstract OT3-04-02: DETECT III and IV – Individualized CTC-based therapy of metastatic breast cancer (2017) (1)
Abstract OT1-03-05: The DETECT V-Study – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer (2018) (1)
P277 Simultaneous study of docetaxel based anthracycline free adjuvant treatment evaluation, as well as life style intervention strategies: The German SUCCESS C trial (2011) (1)
0178 Results of clinical endpoints of a randomized phase II trial with doxorubicin + pemetrexed followed by docetaxel versus doxorubicin + cyclophosphamide followed by docetaxel as primary systemic therapy for early breast cancer (2009) (1)
Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study (2014) (1)
Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent but clinically inapparent in cancer patients under immune checkpoint therapy (2021) (1)
Abstract OT2-6-09: 4EVER - A phase IIIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE) (2013) (1)
Impact of mRNA-Assessed Molecular Subtype Conversion, Intact and Apoptotic Circulating Tumor Cells on Survival of Metastatic Breast Cancer Patients: Proof of Principle (2020) (1)
Basoluminal and luminal phenotypes in triple-negative breast cancer: Immunohistochemical profiling and survival. (2011) (1)
Abstract PD7-09: Changes in hormone levels (E2, FSH, AMH) and fertility of young women treated with neoadjuvant chemotherapy (CT) for early breast cancer (EBC) (2018) (1)
COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy (2022) (1)
Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial. (2014) (1)
PROCAPP: A randomized, open-label phase III trial comparing mapisal and urea hand-foot cream as prophylaxis for capecitabine-induced hand-foot skin reaction (HFSR) in patients (pts) with gastrointestinal (GI) tumors or breast cancer—A study of the AIO Quality of Life Working Group. (2014) (1)
Targeted Therapy of HER 2-Negative Breast Cancer (2016) (1)
192 Pertuzumab and Trastuzumab in Combination with an Anthracycline-containing or an Anthracycline-free Standard Chemotherapy in the Neoadjuvant Treatment of HER2-positive Breast Cancer (TRYPHAENA) (2012) (1)
Abstract OT1-1-13: Dual blockade with Afatinib and Trastuzumab as neooadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy (DAFNE)-GBG70 (2012) (1)
Abstract P4-11-21: Prevalence of circulating tumor cells (CTCs) after five years of zoledronate treatment in the adjuvant SUCCESS-A study (2015) (1)
RIBECCA: A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole—Results of the first interim analysis. (2018) (1)
257OINTENSE DOSE-DENSE EPIRUBICIN (E), PACLITAXEL (T), CYCLOPHOSPHAMIDE (C) (IDDETC) IS HIGHLY EFFECTIVE IN ADJUVANT THERAPY OF NODE-POSITIVE BREAST CANCER PATIENTS (PTS). AN ANALYSIS OF THE GBG, AGO-B, AND NOGGO STUDY GROUPS. (2014) (1)
99TiPMutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (2017) (1)
Abstract P1-14-11: nab-paclitaxel at a dose of 125 mg/m2weekly is more efficacious but less toxic than at 150 mg/m2. Results from the neoadjuvant randomized GeparSepto study (GBG 69) (2016) (1)
Diurnal cortisol profile in breast cancer patients before and during treatment with Viscum album (Iscador® P) for 3 or 6 months (2011) (1)
Feasibility and sociopsychological impact of video consultations in medical oncology - a randomized controlled open label trial (2020) (1)
[Taxane-based palliative chemotherapy for metastatic breast cancer: matched pair analysis to compare the efficacy and safety of docetaxel and paclitaxel]. (2001) (1)
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]. (2022) (1)
Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958) (2022) (1)
Spinale Mammakarzinommetastasen aus Sicht der Wirbelsäulenchirurgie (2018) (1)
Prognostische Relevanz des HER2/neu Status für das Überleben von Brustkrebspatientinnen (2013) (1)
Mammakarzinom in der Schwangerschaft (2018) (1)
Her2-Expression zirkulierender Tumorzellen bei Patientinnen mit Her2 positivem Mammakarzinom im Frühstadium vor adjuvanter Chemotherapie – Ergebnisse der SUCCESS B Studie (2012) (1)
Update Mammakarzinom 2019 Teil 1 – Implementierung der Ergebnisse neuer Studienkonzepte beim frühen Mammakarzinom in die klinische Praxis (2019) (1)
Die operative Therapie des Mammakarzinoms (2009) (1)
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus Erstbehandlung von Patientinnen mit primärem Mammakarzinom: Evidenz, Kontroversen, Konsens (2017) (1)
PO-0969: Stereotactic body radiotherapy in extracranial oligometastatic or oligoprogressive breast cancer (2020) (0)
Molecular techniques for identification of new prognostic and predictive markers (2008) (0)
rs 2735383 , located at a microRNA binding site in the 3 ’ UTR of NBS 1 , is not associated with breast cancer risk (2016) (0)
PerFECT-Pertuzumab in First-Line Treatment of HER2-positive metastatic breast Cancer patients: A cohort-study of patients treated either with docetaxel and Trastuzumab or docetaxel, trastuzumab and pertuzumab (2016) (0)
Update Mammakarzinom 2021 Teil 5 – fortgeschrittenes Mammakarzinom Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer (2022) (0)
Investigating Denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-Paclitaxel schedules – 2 × 2 factorial design (GeparX) (2018) (0)
Abstract P4-07-01: Profiling miRNA in high risk post-operative early breast cancer patients to detect possible association to correlation with immune system antitumor response (2017) (0)
Abstract PD15-06: PD15-06 Pathologic complete response and breast-conserving surgery are associated with improved prognosis in patients with early-stage triple-negative breast cancer treated with neoadjuvant chemotherapy (2023) (0)
N-of-1 Trials in Cancer Drug Development. (2023) (0)
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto (2019) (0)
Speaker Abstracts (2012) (0)
O-81 Interactions of tumorantigen-reactive T-cells derived from bone marrow and tumor-cells in breast cancer patient (2007) (0)
Abstract P6-17-37: Therapy landscape of patients with metastatic, HER2 positive breast cancer - Data from the real world breast cancer registry PRAEGNANT (NCT02338167) (2019) (0)
Abstract P4-21-06: Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial (2017) (0)
Improving personalised therapy in metastatic breast cancer by implementing RNA sequencing based gene expression signatures (2019) (0)
Abstract P1-08-07: High tumor CD68 mRNA content (intratumoral macrophages) predicts response to neoadjuvant chemotherapy (2013) (0)
5038 POSTER Prospective study on helical Tomotherapy as a new technique for whole abdominal irradiation in patients with advanced ovarian cancer (2007) (0)
Abstract PD04-08: Circulating tumor cells (CTC) in peripheral blood of breast cancer patients two years after adjuvant chemotherapy depending on endocrine treatment — The German SUCCESS-Trial (2010) (0)
Patterns and predictors of first-line (1L) taxane use in US patients with metastatic triple-negative breast cancer (mTNBC) (2019) (0)
Die Wirksamkeit von nab-Paclitaxel scheint nicht assoziiert zu sein mit der Expression von SPARC beim metastasierten Mammakarzinom (2014) (0)
Gallen-Konsensuskonferenz ( Wien 2017 ) Initial Treatment of Patients with Primary Breast Cancer : Evidence , Controversies , Consensus Spectrum of Opinion of German Specialists at the 15 th International St . Gallen Breast Cancer Conference ( Vienna 2017 ) (2017) (0)
Erratum to: Current role of liquid biopsy in metastatic breast cancer and future perspectives (2016) (0)
Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer (2017) (0)
Circulating tumor cells (CTCs) in peripheral blood of primary breast cancer patients – translational research program of the German SUCCESS-Trial (2008) (0)
Update Mammakarzinom 2019 Teil 3 – aktuelle Entwicklungen bei der kurativen Behandlung von Mammakarzinompatientinnen: eine Übersicht und Bewertung durch ein internationales Expertenpanel (2019) (0)
Factors Predicting Discordance in HER2 Phenotype between Primary Tumor and Circulating Tumor Cells in Women with Metastatic Breast Cancer (2016) (0)
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry. (2022) (0)
Update Mammakarzinom 2021 Teil 2 – fortgeschrittene Stadien, Langzeitfolgen und Biomarker (2022) (0)
Low Positivity for Hormone Receptors in Early Breast Cancer: Therapy-Response and Prognosis -A Systematic Analysis of a Total of 9027 Patients (2019) (0)
21P BACH1 and HIF1α predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC) (2021) (0)
Quality of life and fatigue in breast and gynecologic cancer patients during chemotherapy supported by a complex nurse-led CAM intervention (2017) (0)
The triplet gemcitabine (G), epirubicin (E) and docetaxel (Doc) is feasible, safe and highly active as primary systemic therapy (PST) of patients (pts) with multicentric phase I/II trial (2003) (0)
Maintenance of Quality of Life in Patients with Malignant Ascites During Treatment with the Trifunctional Antibody Catumaxomab: Results from the Phase III B Casimas Trial (2012) (0)
Abstract P6-15-03: Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials (2018) (0)
Neoadjuvant epirubicin, gemcitabine, and docetaxel for primary breast cancer: Survival and prognostic factors in two consecutive neoadjuvant phase I/II trials. (2012) (0)
Abstract PS2-02: Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program (2021) (0)
Prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy in patients with HER2-negative early breast cancer (EBC). (2013) (0)
Abstract P1-11-01: Effectiveness, safety and quality of life (QoL) results from the German multicenter AVANTI study of 1st-line bevacizumab (BEV)-containing therapy in >2000 patients (pts) with advanced breast cancer (aBC) (2018) (0)
Abstract 1987: Molecular characterization of the breast cancer-associated antigen NY-BR-1 (2015) (0)
66P Baseline menopausal status, Ki-67 and stromal tumour-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): Exploratory analysis in GeparSixto (2021) (0)
Inhalt Band 6, 2011 (2011) (0)
281PCell-free circulating DNA as independent prognostic markers in metastatic breast cancer (2017) (0)
Chemotherapy-induced amenorrhea in premenopausal breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy within the SUCCESS study. (2012) (0)
„Breast-like cancer of unknown primary“ (2023) (0)
Management of the axilla for high-risk early breast cancer (EBC) before and after neoadjuvant chemotherapy (NACT): an analysis of the multicentre GeparOcto trial (2020) (0)
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab (2022) (0)
Return of individual genomic research results within the PRAEGNANT multicenter registry study (2022) (0)
Abstract P3-14-01: Features of neoadjuvant and adjuvant chemotherapy in breast cancer – A population-based study on 39404 patients (2013) (0)
IMpassion130: Efficacy in immune biomarker subgroups of atezolizumab plus nab-paclitaxel in patients with triple-negative BC (2019) (0)
Mammakarzinom junger Patientinnen (bis 35 Jahre): Prognostische Bedeutung von Histopathologie, Tumorstadium und klinischer Parameter (2005) (0)
Abstract P2-11-04: Efficacy and safety of darbepoetin alfa or epoetin beta in 2994 high risk early breast cancer patients participating in the German adjuvant intergroup node-positive study (GAIN) (2017) (0)
Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC) (2019) (0)
Abstract P6-15-01: Withdrawn (2018) (0)
Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer (2022) (0)
Klinische und tumorbiologische Charakterisierung von Langzeitüberlebenden mit fortgeschrittenem Mammakarzinom nach Hochdosischemotherapie und Transplantation autologer, hämatopoetischer Stammzellen (2003) (0)
Physical Performance In Breast Cancer Patients Undergoing Adjuvant Therapy: 1391 Board #131 May 29, 9 (2014) (0)
Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry (2017) (0)
Impact of the trifunctional antibody catumaxomab followed by systemic chemotherapy (CTX) on overall survival (OS): Results of a subgroup analysis in patients (pts) with relapsed ovarian cancer (OC) and malignant ascites (MA). (2013) (0)
Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients (2018) (0)
Abstract P6-04-14: Integrating whole genome sequencing data with RNAseq, pathway analysis, and quantitative proteomics to determine prognosis after standard adjuvant treatment with trastuzumab and chemotherapy in primary breast cancer patients (2016) (0)
Abstract P1-14-01: Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. (2012) (0)
Treatment tolerability and toxicity of postoperative proton beam therapy for gynecological malignancies - results of the prospective phase II APROVE-trial. (2023) (0)
P1-14-04: Prolonged (≥1 Year) Exposure to First-Line Bevacizumab Combined with Paclitaxel in Patients with HER2−Negative Metastatic Breast Cancer Treated in a Routine Oncology Practice Study. (2011) (0)
Contents Vol. 6, 2011 (2011) (0)
P26 Gene expression profiles can predict pathologiccomplete response to preoperative chemotherapy with gemcitabine, epirubicin and docetaxel in primary breast cancer (2005) (0)
Abstract 3154: Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1 (2015) (0)
Development and validation of a new prognostic score on 4,646 patients with luminal-like breast cancer (BC) enrolled in 7 randomized prospective trials. (2016) (0)
Abstract P1-08-15: Prognostic value of five different histologic scoring systems for tumor regression after neoadjuvant chemotherapy of breast cancer in luminal type breast cancer (2013) (0)
Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal b/HER2 normal breast cancer (GENEVIEVE). (2013) (0)
Abstract P3-10-01: Single-cell profiling identifies hypoxic carcinoma cells as source of an immunosuppressive VEGFA metagene (2019) (0)
Abstract P3-06-04: Differences in survival among women with primary and secondary metastatic breast cancer (2013) (0)
480 Evidence from the phase III AVADO study reveals no increase in tumour malignant potential following treatment of metastatic breast cancer (mBC) with bevacizumab (BV) and docetaxel (D) (2010) (0)
Mistletoe lectin- (ML-1) and viscotoxin (VT) antibodies during therapy with Viscum album in patients with breast cancer (2015) (0)
247P Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptor–positive advanced breast cancer (ABC): Secondary and exploratory results of phase 3b RIBECCA study (2021) (0)
Meetings and Conferences · Tagungen und Kongresse (2012) (0)
KI67 and p53 are not predictive of tumor response or survival with trastuzumab-based therapy in metastatic breast cancer patients (pts) with her2/neu-overexpression (2001) (0)
Correlation of BMI with tumor stage in early breast cancer patients (pts): Pooled analysis of the German SUCCESS A, B, and C trials. (2012) (0)
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. (2022) (0)
Abstract PD14-06: Dynamic changes of PD-L1 and T-cell activation in ECLIPSE: A phase II study investigating preoperative immune combination strategies in untreated, operable ER+ primary breast cancer (2021) (0)
Reprogrammingof theERR a andER a TargetGene Landscape Triggers Tamoxifen Resistance in Breast Cancer (2015) (0)
16 Circulating tumour cells (CTCs) can be detected in peripheral blood of breast cancer (BC) patients two years after primary diagnosis (2010) (0)
Toxicity analysis of a phase III study evaluating FEC-Doc vs. FEC-Doc in combination with gemcitabine as adjuvant treatment for breast cancer – the SUCCESS-trial. (2009) (0)
Komplementärmedizinische Pflege- und Beratungsmaßnahmen in der gynäkologischen Onkologie: eine präferenzbasierte, teilrandomisiert-kontrollierte Studie (CONGO Studie) (2014) (0)
Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference (2022) (0)
Response to Di Cosimo, Torri, and Porcu. (2019) (0)
Genome-wide association study of germline variants and breast cancer-specific mortality (2019) (0)
Abstract PD14-05: Genomic profiling and clinical outcomes with first-line atezolizumab andnab-paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial (2021) (0)
Abstract P6-13-02: Efficacy of first-line bevacizumab (BEV)-containing therapy for poor-prognosis advanced breast cancer (aBC): Subgroup analyses of the German AVANTI observational study (2017) (0)
Update Mammakarzinom 2019 Teil 1 – Implementierung der Ergebnisse neuer Studienkonzepte beim frühen Mammakarzinom in die klinische Praxis (2019) (0)
Abstract OT3-02-09: Seraphina – Safety efficacy and patient reported outcomes of advanced breast cancer patients: Therapy management with NAB-paclitaxel in daily routine (2016) (0)
1869 Disease characteristics of subgroup patients treated with everolimus + exemestane for <12 months, ≥12 to <18months, and ≥18 months - Results of the 3rd interim analysis of the non-interventional trial BRAWO (2015) (0)
Extensive Genital and Gluteal Epitheliolyses Caused by Locoregional Lichen Ruber Two Years after Primary Treatment of Vulvar Cancer (2008) (0)
Changes in circulating tumor cell counts during the course of chemotherapy in women with high-risk early breast cancer. (2016) (0)
Receptor discordance between primary tumor and metastasis influences CTC-status (2020) (0)
Genome-wide association study of germline variants and breast cancer-speci ﬁ c mortality (2019) (0)
Abstract P3-12-09: The prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy with and without anthracyclines in patients with HER2-negative early breast cancer (EBC) (2013) (0)
136TiP IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC (2016) (0)
Abstract 3973: Comparison of different highly sensitive miRNA array platforms for the investigation of circulating cell-free microRNAs in blood (2015) (0)
Implementation of an ePRO Application for Health-Related Quality of Life (HrQoL) in Breast Cancer Patients: Evaluation and Usability Analysis (Preprint) (2019) (0)
4EVER: Untersuchung zirkulierender Tumorzellen mittels einer neuen, filtrationsbasierten Methode im Rahmen einer multizentrischen Phase IIIb-Studie bei postmenopausalen Patientinnen mit HER2negativem, Östrogenrezeptor-positivem fortgeschrittenen Brustkrebs (2013) (0)
Translationale Highlights Mamma- und Ovarialkarzinom 2019 – Immuntherapien, DNA-Reparatur, PI3K-Inhibition und CDK4/6-Therapien (2020) (0)
Progressive Resistance Training In Breast Cancer Patients Undergoing Adjuvant Therapy: Adherence To Training Principles (2017) (0)
4EVER: Eine offene, multizentrische Studie der Phase IIIB, mit einer Kombinationstherapie von Everolimus (RAD001) und Exemestan bei postmenopausalen Frauen mit Östrogenrezeptor-positivem, lokal fortgeschrittenem oder metastasiertem Brustkrebs (2012) (0)
First-in-Class-Therapie mit Sacituzumab Govitecan (2022) (0)
Detection of circulating tumor cells during long-term follow-up of high-risk breast cancer patients indicates poor prognosis – results of the adjuvant SUCCESS A trial (2016) (0)
Abstract OT3-18-01: Detect III/IV study trial - The multicenter study program in patients with HER2-negative MBC and circulating tumor cells (2020) (0)
P033 Mcl-1 confers protection of breast cancer cells exposed to hypoxia: therapeutic implications (2015) (0)
Abstract P4-13-07: Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER+ women - Results of the 3rd interim analysis of BRAWO (2016) (0)
Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study (2019) (0)
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy. (2023) (0)
Abstract P4-01-08: Persistence of circulating tumor cells immediately after and two years after systemic adjuvant chemotherapy in patients with early breast cancer – Results of the German SUCCESS trials (2015) (0)
Title Page / Table of Contents / Imprint / Guidelines for Authors (2015) (0)
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial (2020) (0)
Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update (2021) (0)
Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy (2023) (0)
Prognostic impact of changes in circulating tumor cells (CTC) in metastatic breast cancer (MBC). (2013) (0)
Abstract P3-06-04: 4EVER: The impact of mTOR inhibition on bone health in postmenopausal women with hormone receptor positive (HR+) advanced breast cancer treated with everolimus (EVE) in combination with exemestane (EXE) (2015) (0)
Editorial Board / Contents / Imprint (2015) (0)
Willingness for the participation in a randomized study on mistletoe treatment - results of a survey including 165 cancer patients from a German university women's hospital. (2009) (0)
Adjuvant Radiation Therapy for Male Breast Cancer—A Rare Indication? (2020) (0)
Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer (2017) (0)
Update Breast Cancer 2022 Part 1 – Early Stage Breast Cancer (2022) (0)
Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies (2022) (0)
Common germline polymorphisms associated with breast cancer-specific survival (2015) (0)
Discordance between HER2-phenotype on circulating tumor cells and primary tumor in women with advanced breast cancer. (2015) (0)
Impact of reproductive factors on breast cancer subtypes in postmenopausal women: a retrospective monocentric study (2016) (0)
Neue Untersuchungen dokumentieren eine hohe Versorgungsqualität an Brustkrebszentren (2011) (0)
Circulating tumour cells, circulating tumour DNA and circulating microRNA in metastatic Breast carcinoma (2017) (0)
Abstract OT1-14-02: Phase 3 study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09 (2022) (0)
Treatment with mistletoe extract in patients with breast cancer, a feasibility study to identify surrogate parameters for further studies - design and first results on recruitment, compatibility and safety. (2009) (0)
Abstract P1-03-05: SPARC expression in primary metastatic breast cancer (2016) (0)
Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study (2016) (0)
Reply to S. Iwase et al. (2016) (0)
Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). (2018) (0)
RIBECCA: A phase IIIb, multicenter, open label study for women with estrogen receptor-positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole—Results of the second interim analysis. (2019) (0)
138P Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC) (2021) (0)
Dose Dependent Effects of G-CSF on Ca27.29 in Early Stage Breast Cancer Patients. (2009) (0)
Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as well as Life Style Intervention Strategies – SUCCESS C-Studie (2010) (0)
Exercise Maintenance After a Randomized Resistance Training Intervention in Breast Cancer Survivors Undergoing Adjuvant Therapy: 2414 Board #5 June 2 9 (2017) (0)
Prevalence of thyroid dysfunction in metastasized breast cancer (2019) (0)
Abstract P1-10-01: Caveolin gene expression predicts for response and clinical outcomes of patients treated with preoperative paclitaxel-based chemotherapy regimens in early stage breast cancer (2020) (0)
In silico SNP analysis of the breast cancer antigen NY-BR-1 (2016) (0)
Update Mammakarzinom 2022 Teil 1 – Brustkrebs in frühen Krankheitsstadien (2022) (0)
Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine (2020) (0)
Abstract P4-07-65: Effect of sacituzumab govitecan vs chemotherapy in HR+/HER2- metastatic breast cancer: patient-reported outcomes from the TROPiCS-02 trial (2023) (0)
Contents of Forthcoming Issues · Themenvorschau (2008) (0)
Das DETECT-Studienkonzept – Zirkulierende Tumorzellen beim metastasierten Mammakarzinom (2016) (0)
Abstract P4-01-03: Prognostic relevance of circulating tumor cells across different molecular subgroups in the adjuvant SUCCESS-A study (2015) (0)
Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer—An Analysis of the NOGGO/JAGO (2023) (0)
Antibiotics post transplant Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation (2002) (0)
Maintenance of quality of life (QoL) and general health state in patients with malignant ascites during treatment with the trifunctional antibody catumaxomab: results from the phase III b CASIMAS trial (2012) (0)
Investigation of Global Methylation in Peripheral Blood from Breast Cancer Patients (2017) (0)
Abstract P2-16-03: Mature results on metastatic breast cancer patients with prolonged (≥1 year) exposure to first-line bevacizumab combined with paclitaxel from a large observation study (2013) (0)
Outcome after neoadjuvant chemotherapy in progesterone receptor negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials (2017) (0)
Abstract PS10-17: Palbociclib (P) in combination with fulvestrant (F) or letrozole (L) in endocrine-sensitive patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC): detailed safety analysis from a multicenter, randomized, open-label, phase II trial (PARSIFAL) (2021) (0)
DETECT III und IV Studien (2018) (0)
Scientific sessionCancer evaluation2353: Sternal/parasternal metastases in breast cancer—differential diagnosis by ultrasound (2006) (0)
Use of chemotherapy for early breast cancer in Germany, 2008-2017: A nationwide time-trend analysis (2020) (0)
Abstract P1-07-12: Prognosis of clinico-pathological breast cancer subtypes in routine clinical care (2016) (0)
2001 ORAL Circulating tumor cells (CTCs) in peripheral blood of primary breast cancer patients – Results from the translational research program of the German SUCCESS-Trial (2007) (0)
SPARC expression in primary metastatic breast cancer (2015) (0)
Machine Learning and Patient-reported Outcomes for Longitudinal Monitoring of Disease Progression in Metastatic Breast Cancer: A Multicenter, Retrospective Analysis (2023) (0)
P102 Cellular immunotherapy in late stage breast cancerpatients with reactivated autologous Memory T-cells derived from bone marrow (2005) (0)
Kongresssplitter DKK 2016 (2016) (0)
Metastasis-initiating cells induce and exploit a fibroblast niche to fuel malignant colonization of the lungs (2020) (0)
Inferred immune-cell activity is an independent predictor of HER2 negative breast cancer prognosis and response to paclitaxel-based therapy in the GeparSepto trial. (2023) (0)
KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer (2019) (0)
Abstract P5-16-03: Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomized GeparSepto study (GBG 69) (2017) (0)
98P Final results from AVANTI, a multicentre German observational study of first-line bevacizumab (BEV) + chemotherapy (CT) in >2000 patients (pts) with advanced breast cancer (aBC) (2021) (0)
Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; volume 32: 983-993. (2021) (0)
Abstract P2-02-06: Impact of apoptotic circulating tumor cells in metastatic breast cancer (2016) (0)
Abstract P6-06-32: 4EVER: Does mTOR inhibition have a major clinical impact on bone health in postmenopausal women with hormone receptor positive (HR+) locally advanced breast cancer treated with everolimus (EVE) in combination with exemestane (EXE)? (2013) (0)
Oblimersen (O) in combination with docetaxel (T), adriamycin (A), and cyclophosphamide (C) as neoadjuvant systemic therapy (NST) in primary breast cancer (PBC): Final results of a multicentric phase I study (2016) (0)
Das metastasierte Mammakarzinom – Medikamentöse Therapie individuell nach Patientin und Tumor (2015) (0)
Pairwise relationships between relative mRNA expression levels of ERR α and selected receptors , cofactors , and target genes in breast cancer tissues ( tumor set I , n = 48 ) (2009) (0)
Abstract OT1-01-05: AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cance (2020) (0)
Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study (Preprint) (2020) (0)
Post-Neoadjuvant Therapy (2019) (0)
Abstract PD2-01: Exploring CDK4/6 inhibitor therapy response and drug resistance development at the single cell level in metastatic breast cancer CTCs (2020) (0)
Abstract P6-13-01: Withdrawn (2018) (0)
Additional file 2: Table S5. of Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study (2016) (0)
PIK3CA mutations in primary HER2-positive and triple negative breast cancer. (2013) (0)
Abstract P2-05-25: Predictive value of ultra-high ESR1 mRNA expression in early breast cancer (2017) (0)
5072 POSTER First-Line Bevacizumab (Bev) Combined With Paclitaxel (pac) in Older Patients (pts) Treated for HER2-Negative Metastatic Breast Cancer (mBC) in a Routine Oncology Practice Study (2011) (0)
Die SUCCESS-Studie – Toxizitätsanalyse einer Phase III Studie mit Docetaxel und Gemcitabine in der adjuvanten Therapie des MammaCA (2008) (0)
Abstract B054: Evaluation of NY-BR-1 as a suitable antigen for CAR based immunotherapy (2016) (0)
Health-related quality of life and patient-reported symptoms after postoperative proton beam radiotherapy of cervical and endometrial cancer: 2-year results of the prospective phase II APROVE-trial (2023) (0)
Abstract P2-12-08: Impact of summation dose intensity product on pathologic response in patients receiving neoadjuvant chemotherapy for early breast cancer (2022) (0)
Correlation of microRNA expression in matched-paired primary tumor, metastasis and plasma samples of metastatic breast cancer patients (2019) (0)
Abstract OT1-12-07: A phase 2 study of chemotherapy de-escalation using a pathological response-guided strategy in patients with HER2-positive, low-risk early breast cancer: PHERGain-2 (2022) (0)
The role of surgery in patients with primary metastatic breast cancer (PMBC) receiving monoclonal antibody treatment. (2014) (0)
Current role of liquid biopsy in metastatic breast cancer and future perspectives (2016) (0)
Abstract 1220:PIK3CAmutations in primary HER2-positive and triple negative breast cancer. (2013) (0)
Fall aus dem Tumorboard – 45-jährige Patientin mit unilateralem, nodal-positivem und invasiv-duktalem Mammakarzinom – histologisch präoperativ als DCIS G3 gesichert (2012) (0)
[Prognostic factors in carcinoma of the breast. Thereupon depends success of the treatment]. (2003) (0)
Abstract P2-02-02: Predictors for discordance in HER2 phenotype between primary tumor and circulating tumor cells in women with metastatic breast cancer (2016) (0)
Additional file 3: Table S6. of Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study (2016) (0)
Abstract PD2-2: Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer (2015) (0)
Abstract P6-10-03: Germline(g)BRCA1/2mutations (m) and hematological toxicities in patients (pts) with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT) (2020) (0)
Additional file 1: Table S4. of Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study (2016) (0)
Age-Dependent Hematologic Toxicity Profiles and Prognostic Serologic Markers in Postoperative Radiochemotherapy Treatment for Uterine Cervical Cancer (2022) (0)
[Breast-like cancer of unknow primary : Implications for radiological diagnostics]. (2023) (0)
Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy (2022) (0)
Abstract OT1-11-02: PRAEGNANT - Real world evidence, translational research, big and smart data: A prospective academic translational research network for the optimization of the oncological health care quality in the adjuvant and advanced/ metastatic setting (NCT02338167) (2019) (0)
Abstract P1-01-03: Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients – Results from the adjuvant SUCCESS A trial (2017) (0)
Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice Update Mammakarzinom 2019 Teil 2 – (2019) (0)
The PACOVAR-trial: A multicenter phase I trial of pazopanib (GW786034) and metronomic cyclophosphamide in patients with recurrent platinum-resistant ovarian cancer (2016) (0)
Cut-off Analysis of HLA-A and HLA-B/C Expression as a Potential Prognosticator of Favorable Survival in Patients With Metastatic Breast Cancer (2023) (0)
Abstract CT015: Phase I dose-escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer (2019) (0)
Allgemeines Umweltrecht (2019) (0)
Use of chemotherapy for early breast cancer in Germany, 2008-2017: A nationwide time-trend analysis (2020) (0)
Predictive value of CD24 ala/val polymorphism for pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer. (2010) (0)
Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients (2014) (0)
63 Circulating Metastasis-initiating Cells in Breast Cancer (2012) (0)
17P Impact of body mass index (BMI) on prognostic and predictive value of stromal tumour-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): A pooled analysis of six neoadjuvant trials (2021) (0)
Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer (2022) (0)
Prognostic score for Luminal A-like breast cancer patients. (2014) (0)
A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer (2018) (0)
Chemotherapy for metastatic breast cancer (2015) (0)
847 Identification of a Biomarker Signature to Predict the Need for Chemotherapy in Patients With Hormone Receptor Positive Breast Cancer (2012) (0)
Multiomic approach to determine prognosis for patients with HER2-positive breast cancer (2016) (0)
Intensity Modulated Whole Abdominal Radiotherapy as a Consolidation Therapy for High-risk Stage FIGO III Patients with Ovarian Cancer: 2 Years Experience of a Single Institution (2009) (0)
Fatal events during clinical trials: an evaluation of deaths during breast cancer studies (2019) (0)
Abstract P1-07-20: Developing prognostic indicators of poor outcomes in PRAEGNANT metastatic breast cancer cohort (2018) (0)
Abstract P5-10-17: Evaluation of PgR status by immunohistochemistry may be inferior to PgR results by Oncotype DX for assessing the recurrence risk in ER+/HER2- breast cancer with low or intermediate tumor proliferation (2015) (0)
Detection and Isolation of Circulating Tumor Cells from Breast Cancer Patients Using CUB Domain-Containing Protein 1. (2023) (0)
OP-JNCI180093 69..77 (2019) (0)
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. (2023) (0)
The Prognostic Benefit of Early Postoperative Radiotherapy and Diagnostic Value of Serologic Markers on Women with Uterine Sarcoma and Carcinosarcoma (2022) (0)
180 Biomarker discovery in plasma of breast cancer patients using microspot immunoassays (2010) (0)
Treatment of locoregional recurrence, with special consideration of HER2-positive recurrences (2013) (0)
Zirkulierende Tumorzellen, zirkulierende Tumor-DNA und zirkulierende microRNA beim metastasierten Mammakarzinom – oder: Welche Rolle spielt die Liquid Biopsy beim Brustkrebs? (2019) (0)
5168 Circulating tumor cells (CTCs) in peripheral blood of breast cancer (BC) patients two years after primary diagnosis – Results from the German SUCCESS trial (2009) (0)
Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer. (2009) (0)
Identification of a blood based metabolomic classifer for the detection of ovarian cancer – MeDOC (2018) (0)
Abstract P2-08-18: Gene and protein expression profiles of HER2, ER, PR, and Ki67 in matched pair samples of primary (PBC) and metastatic breast cancer (MBC) tissues (2016) (0)
Abstract P4-06-01: Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy with durvalumab - Results from the prospectively randomized GeparNuevo trial (2019) (0)
275TiP ASCENT-03: Phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC) (2022) (0)
Cost-effectiveness of anastrozole versus tamoxifen as adjuvant therapy in early breast cancer (EBC) – a German health economic analysis. (2009) (0)
Abstract P3-06-45: Concordance/discordance rates of HER2, ER, PR, and Ki67 in matched pair samples of primary (PBC) and metastatic breast cancer (MBC) tissues when comparing IHC with MammaTyper® RT-PCR kit (2015) (0)
Fulvestrant, eine kostennutzwerte Option in der palliativen Situation. – Ergebnisse des German Faslodex® health economic sequencing model (2008) (0)
Abstract P4-01-01: Presence of circulating tumor cells in high-risk early breast cancer do not predict site of metastatic lesions - Results of the SUCCESS A trial (2020) (0)
Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer. (2022) (0)
Evaluation of CA 27.29 as Prognostic Marker in Primary Breast Cancer Patients – Results of the German SUCCESS Trial. (2009) (0)
Quality of life in patients with malignant ascites during catumaxomab treatment: Results from the CASIMAS trial. (2012) (0)
5074 First-line bevacizumab (bev) plus paclitaxel (pac) combination therapy: safety findings (n = 165) from a multicentre German non-interventional study in patients with metastatic breast cancer (MBC) (2009) (0)
Schwellenwert-Analyse der CTC-Veränderung unter Therapie zur Definition eines Therapieansprechens beim metastasierten Mammakarzinom (2020) (0)
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study (2014) (0)
311P Pooled-analysis of prospective observational studies evaluated the effectiveness and safety of bevacizumab and paclitaxel as the first-line chemotherapy for HER2-negative metastatic breast cancer (2020) (0)
Additional file 1: of Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer (2017) (0)
Abstract P4-04-14: Immunological markers in patients with breast cancer occurring during pregnancy - Results from GBG BCP study (2022) (0)
COMBATing Breast Cancer: Conference on Molecular Basics and Therapeutic Implications in Breast Cancer (2009) (0)
Association of HER2 overexpression and prognosis in small primary breast cancer. (2010) (0)
Impact of prognostic factors on long-term outcomes in metastatic breast cancer (MBC) patients (pts) receiving bevacizumab (B) plus paclitaxel as first-line cytotoxic treatment. (2014) (0)
Abstract OT2-07-01: DETECT V/CHEVENDO – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer (2019) (0)
Langzeit-Ergebnisqualität eines zertifizierten Brustzentrums in Deutschland (2015) (0)
COGNITION – Präzisionsmedizin bei Brustkrebs im Frühstadium (2020) (0)
Wie hat sich die Anwendung von adjuvanter zu neoadjuvanter Chemotherapie beim frühen Mammakarzinom verändert? – Daten von 104 deutschen Brustzentren 2008-2017 (2020) (0)
Zugangswege und Versorgungsrealität bei Männern mit Mammakarzinom – Daten aus dem Brustzentrum Heidelberg (2003 – 2016) (2018) (0)
Persistenz zirkulierender Tumorzellen (CTCs) im peripheren Blut zwei Jahre nach Primärdiagnose (2009) (0)
Update Mammakarzinom 2018 (Teil 1) – primäres Mammakarzinom und Biomarker (2018) (0)
Was gilt, wenn kein Bebauungsplan existiert? (2019) (0)
Behandlung von Patientinnen mit frühem Mammakarzinom: Evidenz, Kontroversen, Konsens (2019) (0)
Two-Gene-Ratio aus ESR1 und MMP7 als Prognoseparameter nach neoadjuvanter Chemotherapie (NACT) (2012) (0)
Abstract PD4-02: PD4-02 Spatial and temporal heterogeneity of predictive and prognostic signatures in triple-negative breast cancer treated with neoadjuvant combination immune-chemotherapy (2023) (0)
Therapieevaluation palliativer Chemotherapien beim metastasierten Mammakarzinom anhand des web-basierten EQ-VAS Scores (2020) (0)
Update Mammakarzinom 2019 Teil 3 – aktuelle Entwicklungen bei der kurativen Behandlung von Mammakarzinom-Patientinnen: Eine Übersicht und Bewertung durch ein internationales Expertenpanel (2019) (0)
Axilläres operatives Management bei befallenen Sentinel-Lymphknoten in einer deutschlandweiten Mammakarzinom-Kohorte (2018) (0)
Die Dreierkombination Gemcitabin, Epirubicin und Docetaxel als primäre systemische Therapie (PST) beim primären Mammakarzinom T2–4, N0–2, M0: Analyse primärer und sekundärer Studienendpunkte einer multizentrischen Phase I/II-Studie (2003) (0)
Systemische Therapie des Mammakarzinoms (2005) (0)
Bauleitpläne (2019) (0)
Beständigkeit und Wandel (2022) (0)
Update Mammakarzinom 2020 Teil 5 – Einführung von Substanzen aus der metastasierten Therapiesituation in die frühe Therapiesituation (2021) (0)
Therapiealgorithmen für das Mammakarzinom (2021) (0)
Statement des BRCA-Netzwerks zu prophylaktischen Maßnahmen bei familiärer Disposition / Spagat zwischen Klinik und Forschung: Der Weg einer jungen Wissenschaftlerin (2011) (0)
Randomisierte prospektive Studie zur Ermittlung der Effektivität und Lebensqualität der Kopfhautkühlung zur Vermeidung einer Chemotherapie-induzierten Alopezie unter (neo-) adjuvanter Chemotherapie bei primärem Mammakarzinom – COOLHAIR-Studie (2016) (0)
Das Mammakarzinom – Wo stehen wir heute, wo gehen wir hin? (2009) (0)
Grundlagen der zytostatischen Systembehandlung in der gynäkologischen Onkologie (2009) (0)
Einführung und Verwendung von biosimilaren Antikörpern in der Therapie des Mammakarzinoms (2017) (0)
Zielgerichtete Therapien – Quo vadis? (2012) (0)
Prädiktion einer pathologischen Komplettremission nach neoadjuvanter Chemotherapie bei Brustkrebs mithilfe bildgebender und pathologischer Befunde (2014) (0)
Einführung und Verwendung von biosimilaren Antikörpern in der Therapie des Mammakarzinoms (2018) (0)
Die adoptive Immuntherapie (ADI) des metastasierten Mammakarzinoms als translationaler Therapieansatz (2009) (0)
Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC) (2020) (0)
Zirkulierende Tumorzellen, zirkulierende Tumor-DNA und zirkulierende microRNA beim metastasierten Mammakarzinom – oder: Welche Rolle spielt die Liquid Biopsy beim Brustkrebs? (2018) (0)
The SUCCESS-Trial -toxicity analysis of a phase III study evaluating the role of Docetaxel and Gemcitabine in the adjuvant therapy of breast cancer patients (2008) (0)
Welche Patientin mit frühem Mammakarzinom braucht eine Chemotherapie? (2011) (0)
Einsatz einer Kombinationschemotherapie mit Mitomycin/ Folinat/ 5-Fluorouracil (5-FU) in der palliativen Therapie bei Patientinnen mit hepatisch metastasiertem Mammakarzinom und eingeschränkter Leberfunktion (2006) (0)
Leitlinienkonformität in Brustzentren zur Vermeidung von Unter- und Übertherapien (2019) (0)
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2020) (0)
Konkordanz-Analyse von Primärtumor, Metastase und CTC mithilfe von IHC, RT-PCR und CellSearch bei metastasiertem Mammakarzinom (2015) (0)
Case report: Elektrochemotherapie (ECT) zur Tumorkontrolle bei metastasiertem Mamma-CA mit kutanen Filiae (2015) (0)
Fulvestrant, eine kostennutzwerte Option in den unterschiedlichen Therapieszenarien der palliativen Situation – Ergebnisse des Faslodex® Gesundheitsökonomiemodells (2008) (0)
Update Mammakarzinom 2022 Teil 4 – Brustkrebs in fortgeschrittenen Krankheitsstadien (2022) (0)
Update Mammakarzinom 2019 Teil 4 – diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien für Patientinnen mit frühem Mammakarzinom (2019) (0)
Update Mammakarzinom 2022 Teil 2 – Brustkrebs in fortgeschrittenen Krankheitsstadien (2022) (0)
Tumor-reaktive T-Zellen als mögliche translationale Therapieoption beim metastasierten Mammakarzinom (2012) (0)
Einfluss HER2-gerichteter Therapien auf den CTC-Status beim metastasierten Mammakarzinom (2019) (0)
Chemotherapie-Anwendung beim frühen Mammakarzinom in Deutschland – aktuelle Daten aus 179 Brustkrebszentren (2008 – 2015) (2018) (0)
Mammakarzinom : Prädiktive Marker für die Therapieoptimierung (Leitthema) (2009) (0)
Zielgerichtete Therapien - Die Bedeutung der Angiogenesehemmung in der Therapie des Mammakarzinoms (2008) (0)
Zelluläre Immuntherapie beim fortgeschrittenen Mammakarzinom mittels tumorantigenspezifischer reaktivierter, autologer T-Memory-Zellen des Knochenmarks im Sinne einer Phase-I-Studie (2003) (0)
Nachweis zirkulierender Tumorzellen (CTC) im peripheren Blut von Patientinnen mit primärem Mammakarzinom (2007) (0)
Therapieoptionen beim hormonrezeptorpositiven, HER‑2-negativen metastasierten Mammakarzinom (2020) (0)
Vergleich der Anzahl zirkulierender Tumorzellen mit dem Proliferationsmarker Ki-67 beim metastasierten Mammakarzinom (2018) (0)
Antiangiogenese in der Brustkrebstherapie (2011) (0)
Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer (2015) (0)
Kongressrückblick. „Wir sind Senologie“ (2015) (0)
Aufhebung von Bauleitplänen (2019) (0)
Teilbaugenehmigung (2019) (0)
Rückblick – Stimmen zum DGS-Kongress (2013) (0)
4EVER: Hat die Inhibition von mTOR einen wesentlichen klinischen Einfluss auf die Knochengesundheit postmenopausaler Frauen mit Östrogenrezeptor-positivem, lokal fortgeschrittenem oder metastasiertem Brustkrebs unter Behandlung mit Everolimus (RAD001) und Exemestan? (2013) (0)
Prädiktivfaktoren für die Diskrepanz des HER2-Phänotyps zwischen zirkulierenden Tumorzellen und Primärtumor bei Patientinnen mit metastasiertem Mammakarzinom (MBC) (2016) (0)
Veränderungen in der Anwendung und beim Outcome von Chemotherapie beim frühen Mammakarzinom in der letzten Dekade (2003 – 2014) (2017) (0)
Circulating tumor cells in metastatic breast cancer: Are they a strong and independent predictor of poor progression-free and overall survival? (2012) (0)
Frühes Mammakarzinom: Aktuelle Strategien in der System- und Radiotherapie (2021) (0)
Tablet-basierte Erhebung der gesundheitsbezogenen Lebensqualität bei adjuvantem und metastasiertem Brustkrebs: Akzeptanz und Reliabilität (2018) (0)
Update Mammakarzinom 2020 Teil 4 – fortgeschrittenes Mammakarzinom (2021) (0)
GAIN2: Adjuvante Phase III Studie zum Vergleich einer intensivierten dosisdichten adjuvanten Therapie mit EnPC im Vergleich zu einer dosisdichten, adaptierten Die Therapie mit dtEC-dtD bei Patienten mit einem frühen Hochrisiko-Brustkrebs (2014) (0)
Evaluation einer elektronischen Erhebung von Patient-reported-Outcomes (PROs) in der PRAEGNANT Studie (2016) (0)
Prognostische Relevanz zirkulierender Tumorzellen (CTCs) im peripheren Blut vor und nach Chemotherapie bei Patientinnen mit primärem Mammakarzinom – Ergebnisse der SUCCESS-Studie (2008) (0)
P5-14-05: Anti-Müllerian Hormone (AMH) Levels in Premenopausal Breast Cancer Patients Treated with Adjuvant Chemotherapy – A Translational Research Project of the SUCCESS Study. (2011) (0)
Erstbehandlung von Patientinnen mit primärem Mammakarzinom: Evidenz, Kontroversen, Konsens (2017) (0)
Update Mammakarzinom 2017 – Etablierung neuer zielgerichteter Therapien (2018) (0)
Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium – Real-World-Daten aus dem PRAEGNANT-Register (2022) (0)
Veränderungen in der Anwendung und beim Outcome von Chemotherapie beim frühen Mammakarzinom in der letzten Dekade (2017) (0)
Interdisziplinäre Tumorkonferenz – Mammakarzinom nach Radiatio im Kindesalter bei Morbus Hodgkin Erkrankung (2013) (0)
Aus dem Tumorboard – Langzeitremission unter T-DM1 + Pertuzumab / Placebo (MARIANNE-Studie) bei einer Patientin mit lokal weit fortgeschrittenem HER2-positiven Mammakarzinom (2015) (0)
Die Deutsche Gesellschaft für Senologie aus Sicht des NCT (2011) (0)
P15 Interactions of tumorantigen-reactive T-cells derived from bone marrow and tumor-cells in breast cancer patients (2007) (0)
Besonderes Umweltrecht (2019) (0)
Ergebnisqualität von Brustkrebs-Subtypen in der klinischen Routine – eine große, prospektive Kohortenstudie (2016) (0)
Bauvorbescheid (2019) (0)
Nachweis von zirkulierenden Tumorzellen bei Patientinnen mit frühem Brustkrebs fünf Jahre nach adjuvanter Chemotherapie und späte Rezidive – Ergebnisse der SUCCESS A Studie (2018) (0)
Untersuchung zirkulierender Tumorzellen im peripheren Blut zur Risikoeinschätzung und Verlaufskontrolle beim primären Mammakarzinom in der SUCCESS-Studie (2008) (0)
Zürich Konsens: Stellungnahme deutscher Experten zum St. Gallen-Votum am 15. März 2009 (2009) (0)
Akzeptanz einer oralen Chemotherapie bei Patientinnen mit metastasiertem Mammakarzinom – eine prospektive Fragebogenevaluation (2010) (0)
Update Mammakarzinom 2022 Teil 3 – Brustkrebs in frühen Krankheitsstadien (2022) (0)
Ergebnisqualität eines zertifizierten Brustzentrums in Deutschland – „proof of principle“ Datenanalyse einer prospektiven Tumordokumentation (2011) (0)
DETECT V – Vergleich der HER2-zielgerichteten dualen Blockade plus Ribociclib in Kombination mit Chemotherapie oder endokriner Therapie bei Patientinnen mit HER2-positivem und HR-positivem metastasiertem Mammakarzinom (2018) (0)
Nutzung eines molekularen Registers (PRAEGNANT) zur Patienten-Selektion und Biomarker-Analyse für die SHERBOC Studie (2020) (0)
Sicherung der Bauleitplanung (2019) (0)
Update Mammakarzinom 2020 Teil 3 – frühes Mammakarzinom (2021) (0)
Molekulare Prädiktoren zur Abschätzung des Therapieansprechens auf eine neoadjuvante Systemtherapie von Patientinnen mit frühem Her2-positivem Mammakarzinom (2019) (0)
Unterschiedliche Zytokinsekretionsprofile bei humanen Mammakarzinomzelllinien – Einfluss auf das Tumor/Host microenvironment und damit auf die Metastasierung? (2006) (0)
Behandlung von Aromatasehemmer assoziierten Arthralgien (2007) (0)
GAIN2: Adjuvante Phase III Studie zum Vergleich einer intensivierten dosisdichten adjuvanten Therapie mit EnPC im Vergleich zu einer dosisdichten, adaptierten Therapie mit dtEC-dtD bei Patienten mit einem frühen Hochrisiko-Brustkrebs: Ergebnisse der zweiten Sicherheitsanalyse (2015) (0)
Phase-II Studie zur Beurteilung der Wirksamkeit und Toxizität der Kombinationschemotherapie mit Taxotere und Gemzar in der First-line-Behandlung beim Her2-negativen und anthracyclinvorbehandelten metastasierten Mammakarzinom (2003) (0)
St. Gallen Konsensus 2007 aus deutscher Sicht - Kommentare einer deutschen Arbeitsgruppe zur Therapie des primären Mammakarzinoms (2007) (0)
Relevanz zirkulierende Tumorzellen (CTCs) vor und nach adjuvanter Chemotherapie – Ergebnisse der SUCCESS-Studie (2010) (0)
Update Mammakarzinom 2018 (Teil 3) – Genomforschung, individualisierte Medizin und Immuntherapien – mitten in einer neuen Ära: Prävention und Therapie des frühen Mammakarzinoms (2019) (0)
Dynamik zirkulierender Tumorzellen unter Chemotherapie und Prognose bei Hochrisiko-Patientinnen mit frühem Mammakarzinom (2016) (0)
Differenz im Überleben zwischen der Mammakarzinompatientinnen mit der primären und sekundären Metastasierung nach Trastuzumab- oder Bevacizumab-haltiger Therapie. (2014) (0)
Zusammenhänge zwischen Mammakarzinomzellen und dem zellulären Immunsystem (2006) (0)
Persistenz zirkulierender Tumorzellen direkt nach und zwei Jahre nach adjuvanter Chemotherapie bei Patientinnen mit früher Brustkrebserkrankung – Ergebnisse der SUCCESS Studien (2016) (0)
DETECT III und IV - Individualisierte CTC-basierte Therapie des HER2-negativen metastasierten Mammakarzinoms (2020) (0)
Überprüfung der Wirksamkeit eines Bauleitplans (2019) (0)
The DETECT Study Concept - Metastatic breast cancer and circulating tumor cells (2016) (0)
Behandlung von medikamentenassoziierten Nebenwirkungen in der gynäkologischen Onkologie (2008) (0)
Einfluss von Nachresektion auf das Lokalrezidivrisiko bei Patientinnen mit Mammakarzinom nach brusterhaltender Therapie (2014) (0)
Effektivität und Verträglichkeit von T-DM 1 bei Patientinnen mit metastasiertem Her2-positivem Mammakarzinom in der klinischen Routine (2015) (0)
Schwangerschaft und Krebs (2018) (0)
Update Mammakarzinom 2018 (Teil 2) – Fortgeschrittenes Mammakarzinom, Lebensqualität und Prävention (2018) (0)
Therapie des frotgeschrittenen HER-2/neu positiven Mammakarzinoms mit der Kombination Capecitabine/Trastuzmab (2004) (0)
EQ-VAS zur Therapieevaluation von palliativen Chemotherapien beim metastasierten Mammakarzinom (2020) (0)
Serielle Bestimmung von zirkulierenden Tumorzellen (CTC) zur Prädiktion von Therapieansprechen und Prognose beim metastasierten Mammakarzinom (MBC) – eine prospektive Studie an 393 Patientinnen (2014) (0)
Evaluierung der Dokumentationsqualität zur Brustzentrumszertifizierung im Rahmen des electronic case report forms (eCRF) der PRAEGNANT-Studie (2016) (0)
Update Mammakarzinom 2019 Teil 2 – Implementierung neuer Diagnostika und Therapien bei Patientinnen mit fortgeschrittenem Brustkrebs in der klinischen Praxis (2019) (0)
Systemtherapie des Mammakarzinoms (2009) (0)
Die SUCCESS-Studie – Toxizitätsanalyse einer Phase III Studie mit Docetaxel und Gemcitabine in der adjuvanten Therapie des frühen Mammakarzinoms (2008) (0)
Quantitative Analyse für ER, PR, HER2 und Ki67 von Primärtumor- und Metastasen-Gewebe bei matched-pair samples mithilfe von RT-qPCR bei Patientinnen mit metastasiertem Brustkrebs (2016) (0)
Ki67 mRNA Einzelgenmessung prädiziert Ansprechen auf Chemotherapie (2012) (0)
Prognostische Bedeutung apoptotischer zirkulierender Tumorzellen (aCTCs) bei metastasiertem Mammakarzinom (MBC) (2015) (0)
AGO-Algorithmen zur Behandlung von Brustkrebs: Update 2021 (2021) (0)
Wie wird heute Chemotherapie beim frühen Mammakarzinom angewendet? – Deutschlandweite Daten aus der letzten Dekade (2008 – 2018) (2019) (0)
Vergleich elektronischer Fragebögen zur gesundheitsbezogenen Lebensqualität (HRQoL) beim metastasierten Mammakarzinom (2020) (0)
Simultane Studie über Docetaxel-basierte anthrazyklinfreie adjuvante Therapie sowie über Lebensstilintervention Success C (2009) (0)
DETECT-V/CHEVENDO (2018) (0)
Zirkulierende Tumorzellen, zirkulierende Tumor-DNA und zirkulierende microRNA beim metastasierten Mammakarzinom – oder: Welche Rolle spielt die Liquid Biopsy beim Brustkrebs? (2018) (0)
Korrelation von Body Mass Index und Tumorcharakteristika bei Patientinnen mit primärem Mammakarzinom – Gepoolte Analyse der SUCCESS A, B und C Studien (2012) (0)
Die DETECT-Studien: zirkulierende Tumorzellen (CTC) beim metastasierten Mammakarzinom (MBC) (2015) (0)
Moderne Senologie aus Sicht der Inneren Medizin (2011) (0)
Zelluläre Immuntherapie beim metastasiertem Mammakarzinom mit reaktivierten T-Gedächtniszellen (2006) (0)
Veränderung des axillären Managements bei Brustkrebspatientinnen mit 1 – 2 tumorbefallenen Sentinel-Lymphknoten (2018) (0)
Abstract GS5-02: Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study (2023) (0)
Dauerhaftes Ansprechen auf Olaparib und endokrine Therapie bei einer Patientin mit metastasiertem luminalem Mammakarzinom und gBRCA-Mutation (2020) (0)
Einfluss des CDK4/6-Inhibitors Ribociclib auf die periphere Immunantwort beim Hormonrezeptor-positiven Mammakarzinom (2020) (0)
Molekulare Subtypisierung auf mRNA Basis prädiziert Therapieansprechen und Überleben nach neoadjuvanter Chemotherapie (2012) (0)
DETECT V/CHEVENDO – duale HER2-zielgerichteten Therapie mit Trastuzumab und Pertuzumab plus Ribociclib in Kombination mit Chemotherapie oder endokriner Therapie bei Patientinnen mit HER2-positivem und hormonrezeptor-positivem metastasierten Mammakarzinom (2020) (0)
Update Mammakarzinom 2020 Teil 1 – frühes Mammakarzinom: Konsolidierung des Wissens über bekannte Therapien (2020) (0)
Update Mammakarzinom 2021 Teil 4 – Prävention und frühe Krankheitsstadien (2022) (0)
Expression des Estrogen-Related Receptor alpha (ERRα) in Mammakarzinomen und dessen Korrelation mit pS2 und AIB1 (2006) (0)
Update Mammakarzinom 2021 Teil 1 – Prävention und frühe Krankheitsstadien (2021) (0)
Davon hängt der Therapieerfolg ab (2003) (0)
Diagnostik und Therapie des triple-negativen Mammakarzinoms (TNBC) – Empfehlungen für die tägliche Routine (2019) (0)
Unterscheidet sich die Chemotherapie-Anwendung beim frühen Mammakarzinom in Deutschland zwischen Zentren unterschiedlicher Versorgungsstufe bzw. mit unterschiedlichen Fallzahlen? (2020) (0)
Eribulin in der Behandlung des fortgeschrittenen metastasierten Mammakarzinoms (MBC): Erste Erfahrungen am Nationalen Centrum für Tumorerkrankungen (NCT) Heidelberg (2012) (0)
Persistenz zirkulierender Tumorzellen im peripheren Blut (CTCs) zwei Jahren nach Erstdiagnose des Mammakarzinoms (2009) (0)
Die Baugenehmigung (2019) (0)
Case-Report: Langzeitremission unter T-DM 1 + Pertuzumab/Plazebo (MARIANNE-Studie) bei einer Patientin mit lokal fortgeschrittenem primär nicht kurativen Her2-positivem Mammakarzinom (2015) (0)
Aus dem Tumorboard – Begrenzt metastasiertes Mammakarzinom einer 90-jährigen Patientin (2013) (0)
Pazopanib und Cyclophosphamid (im Rahmen der PACOVAR-Studie) beim rezidivierten Ovarialkarzinom – ein Fallbericht (2014) (0)
Systemische Therapie operabler Mamma-Karzinome (2005) (0)
Haben Patientinnen mit einer Nachresektion nach BET das gleiche Risiko eines lokoregionären Rezidivs wie Patientinnen mit einzeitiger kompletter Tumorentfernung (2016) (0)
Können zirkulierende Tumorzellen (CTC) im Blut vor und nach einer adjuvanten Chemotherapie als prognostische Marker dienen? – Erste Ergebnisse des translationalen Forschungsprogramms der SUCCESS-Studie (2008) (0)
Zulässigkeit von Vorhaben (2019) (0)
Praktische Erfahrungen mit Eribulin bei metastasiertem Mammakarzinom (2013) (0)
Behandlung des lokoregionären Rezidivs unter besonderer Berücksichtigung der HER2-positiven Rezidive (2013) (0)
Komplettremission bei metastasiertem luminalem Mammakarzinom unter Programmed Cell Death Protein 1 gerichteter Monotherapie: Kasuistik und Implikationen für die Zukunft (2016) (0)
Update Mammakarzinom 2021 Teil 5 – fortgeschrittenes Mammakarzinom (2022) (0)
DETECT III und IV – Individualisierte CTC-basierte Therapie des metastasierten Mammakarzinoms (2017) (0)
Städtebaulicher Vertrag (2019) (0)
Bedeutung und Prognose des Her2/neu-Rezeptors in primären Mammakarzinomen <2cm (T1) (2011) (0)
LIVE-Stream Aufzeichnung vom ASCO 2019: Brustkrebs Deutschland Round Table-Moderation: Renate Haidinger, Brustkrebs Deutschland e.V., München, mit: (2020) (0)
SUCCESS-C Studie: Zwischenanalyse der Toxizität nach Anwendung einer anthrazyklinfreien Chemotherapie in der adjuvanten Behandlung des Her2/neu negativen primären Mammakarzinoms (2011) (0)
Korrelation der CTC-Dynamik und der mRNA-quantifizierten Biomarkerkonvertierung zwischen primärem und metastasiertem Mammakarzinom (2018) (0)
AGO-Empfehlungen zur operativen Therapie der Axilla nach neoadjuvanter Chemotherapie: Update 2021 (2022) (0)
Zelluläre Immuntherapie mittels tumorreaktiver T-Gedächtniszellen des Knochenmarks bei Patientinnen mit metastasierendem Mammakarzinom (2005) (0)
Zirkulierende miRNAs als prognostische und prädiktive Marker beim metastasierenden Mammakarzinom (2011) (0)
Das DETECT-Studienkonzept – Therapie des metastasierten Mammakarzinoms auf der Grundlage zirkulierender Tumorzellen (2016) (0)
Molekulare Prädiktoren zur Abschätzung des Therapieansprechens von Patientinnen mit frühem triple-negativen Mammakarzinom (2018) (0)
15. Internationale St.-Gallen-Konsensus-Konferenz: Behandlung des frühen Mammakarzinoms (2017) (0)
Deutsche Osteoonkologische Gesellschaft (2010) (0)
Tumorbiologie, intratumorale Zytokine und tumorspezifische Immunantworten: Korrelation zur Prognose beim primären Mammakarzinom (2010) (0)
Interaktionen zwischen tumorantigen-reaktiven T-zellen des knochenmarks und tumorzellen bei patientinnen mit mammakarzinom (2006) (0)
Prognostischer Effekt von Änderungen der Anzahl zirkulierender Tumorzellen unter Chemotherapie bei Patientinnen mit frühem Mammakarzinom (EBC) (2016) (0)
Evaluation des MD Anderson Prognostic Index (MDAPI) zur lokoregionären Risikostratifikation in der neoadjuvanten Therapiesituation (2016) (0)
Prädiktive Faktoren für die Diskordanz des HER2-Phänotyps zwischen Primärtumor und zirkulierenden Tumorzellen beim metastasierten Mammakarzinom (2016) (0)
Rückblick – Stimmen zum DGS-Kongress (2013) (0)
Einfluss des Oncotype DX Recurrence Score auf Therapieempfehlungen beim ER-positiven (ER+), nodalnegativen (N0) und nodalpositiven (N+) frühen Mammakarzinom – Ergebnisse einer Interimsanalyse der Deutschen Decision-Impact-Studie (2011) (0)
Abstract P3-14-19: Long-Time Tumor Remissions under Trastuzumab Therapy in HER2- Positive Locally Recurrent or Metastatic Breast Cancer: First Interim Analysis of the HER-OS Database (2010) (0)
Update Mammakarzinom 2019 Teil 2 – Implementierung neuer Diagnostika und Therapien bei Patientinnen mit fortgeschrittenem Brustkrebs in der klinischen Praxis (2019) (0)
Kann eine pathologische Komplettremission nach neoadjuvanter Chemotherapie bei Brustkrebspatientinnen mithilfe einer minimal invasiven Biopsie diagnostiziert werden? Ergebnisse einer prospektiven Pilotstudie (2016) (0)
Die prognostische Bedeutung des Serumwertes von CA27.29 bei Patientinnen mit primärem Brustkrebs vor adjuvanter Chemotherapie – Ergebnisse der SUCCESS-Studiengruppe (2011) (0)
Coolhair – eine prospektive randomisierte Studie zur Ermittlung der Effektivität und Verträglichkeit der Kopfhautkühlung zur Vermeidung einer Chemotherapie-induzierten Alopezie unter (neo-)adjuvanter Chemotherapie bei primärem Mammakarzinom (2017) (0)
Abstract P4-06-10: Immune related gene expression to explore immue escape in primary to metastatic breast cancer transition (2019) (0)
Ein proinflammatorisches Mikromilieu beeinflusst die hepatische Metastasierung von Mammakarzinomzellen (2006) (0)
Effektivität von Kühlung und Kompression der Hände zur Prävention einer Chemotherapie-induzierten Polyneuropathie bei Patientinnen mit primärem Mammakarzinom. Erste Ergebnisse der prospektiven, randomisierten POLAR Studie (2020) (0)
Funktionelle, immunmodulatorische Polymorphismen im TLR-4 Rezeptor und prurinergen Rezeptor P2RX7 und ihr prädiktives Potential im Rahmen einer anthrazyklin- und taxan-basierten neoadjuvanten Chemotherapie bei primärem Mammakarzinom (2011) (0)
Einfluss von Reproduktionsfaktoren auf den Immunophänotyp invasiver Mammakarzinome in der Postmenopause: eine retrospektiv-klinische Studie (2016) (0)
Interdisziplinäre Tumorkonferenz – Korrelation von Pathologie und Bildgebung bei prä- und postoperativen multidisziplinären Tumorkonferenzen (2011) (0)
Protein phosphatase 1 , regulatory subunit 15 B is a survival factor for ER a-positive breast cancer (2013) (0)
Abstract P1-19-31: RIBECCA - A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole: Results of the third interim analysis (2020) (0)
94P Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC) (2022) (0)
Update Breast Cancer 2017 (2017) (0)
Tumor-specific immune response after systemic anti-tumor therapy in patients with primary and metastatic breast cancer and its prediction for systemic relapse (2011) (0)
Abstract P2-16-12: First-Line Bevacizumab Combined with Paclitaxel in Triple-Negative Locally Recurrent/Metastatic Breast Cancer: Subpopulation Analysis of 115 Patients Treated in Routine Oncology Practice in Germany: (2010) (0)
Abstract P6-10-04: Landscape of immune-cell signatures in early high-risk breast cancer (BC) reveals clinically-relevant enrichment of immune subpopulations (2020) (0)
Breast Cancer Treatment with Afinitor (Everolimus) and Exemestane for ER+ Women – Ergebnisse der dritten Interimsanalyse (2015) (0)
Abstract OT2-01-03: DETECT V - Comparison of dual HER2-targeted therapy with trastuzumab and pertuzumab plus CDK4/6 inhibition in combination with either chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer (2020) (0)
Association of rs12662670 with breast cancer in Asian ER (2012) (0)
Immunological effects after an adoptive cellular immunotherapy with reactivated autologous memory T-Cells from bone marrow. (2006) (0)
Abstract P3-07-55: Predictive value of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene methylation in triple-negative breast cancer patients receiving carboplatin (2016) (0)
First-in-Class-Therapie mit Sacituzumab Govitecan (2022) (0)
P4-07-06: Correlation of Two Analytical Methods for Circulating Tumor Cells in Peripheral Blood of Patients with Primary Breast Cancer. (2011) (0)
Palliative Radiotherapy for Symptomatic Locally Advanced Breast Cancer (2023) (0)
Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial (2021) (0)
Autologous Transplantation of Blood Stem Cells Mobilized with Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Subsequent to Chemotherapy for Relapsed Hodgkin’s Disease (1992) (0)
Predictive value of ultra-high ESR1 mRNA expression in early breast cancer. (2016) (0)
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses (2020) (0)
Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications (2015) (0)
Interdisziplinäre Tumorkonferenz - Fälle aus dem Tumorboard – 39-jährige Patientin mit bilateralem, multifokalem, invasiv-duktalem Mammakarzinom mit BRCA1-Mutation (2011) (0)
Erste Ergebnisse aus der randomisierten Phase III Studie DETECT III zur Wirksamkeit des Tyrosinkinaseinhibitors Lapatinib bei der Behandlung von Patientinnen mit HER2-negativem metastasiertem Mammakarzinom und HER2-positiven zirkulierenden Tumorzellen (2021) (0)
Reports of Oncological Societies (2014) (0)
rt-qPCR versus protein-based analysis of receptor conversion from primary to metastatic breast cancer (2019) (0)
Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice (2021) (0)
Impact of mRNA-assessed intrinsic subtype conversion between primary and metastatic breast cancer on survival (2020) (0)
Prospektive randomisierte Studie zu naturheilkundlichen Begleittherapien während Chemotherapie bei Mammakarzinom (2006) (0)
Interactions of breast cancer cells and tumorantigen-reactive T-cells derived from bone marrow (2007) (0)
Impact of body mass index on neoadjuvant treatment outcome (2015) (0)
Molecular and Cellular Pathobiology 19 p 13 . 1 Is a Triple-Negative – Speci fi c Breast Cancer Susceptibility Locus (2012) (0)
HER2 overexpression is associated with shorter disease-free survival (DFS) following neoadjuvant systemic therapy (NST) of primary breast cancer (PBC) patients with gemcitabine (G), epirubicin (E) and docetaxel (Doc) (2007) (0)
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a study in 107 patients (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Andreas Schneeweiss?

Andreas Schneeweiss is affiliated with the following schools:

Paracelsus Medical University
Queen Mary University of London
Karolinska Institute
University of Zurich
University of Cambridge
Heidelberg University
TU Dresden
Harvard University
Medical University of Vienna
Humboldt University of Berlin
University of Sheffield
Uppsala University
Heinrich Heine University Düsseldorf
Technical University of Munich
University of Erlangen–Nuremberg